Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 22, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,275,853
Entity Common Stock, Shares Outstanding		4,379,425
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 4,069	$ 3,928
Accounts receivable, net	3,141	3,390
Inventories	3,009	2,817
Prepaid expenses and other current assets	533	617
Total current assets	10,752	10,752
Property and equipment, net	7,703	10,180
Intangible assets, net	11,325	13,412
Goodwill	8,803	8,803
Other assets	48	46
Total assets	38,631	43,193
Current liabilities:
Note payable	357	339
Current portion of long-term debt	2,387	1,714
Accounts payable	2,277	1,853
Other accrued liabilities	2,360	1,992
Deferred revenues	291	235
Total current liabilities	7,672	6,133
Long-term liabilities:
Long-term debt, net	7,853	9,752
Senior secured convertible debentures, net	0	12,028
Warranty liability	3	105
Deferred tax liability	414	359
Other liabilities	444	97
Total liabilities	16,386	28,474
Commitments and contingencies
Stockholders' equity:
Common Stock, $.001 par value, 150,000,000 shares authorized; 4,304,425 and 2,166,898 shares issued and outstanding as of December 31, 2017 and 2016, respectively	4	2
Additional paid-in capital	251,643	225,289
Accumulated deficit	(229,406)	(210,575)
Accumulated other comprehensive income	0	2
Total stockholders' equity	22,245	14,719
Total liabilities and stockholders' equity	38,631	43,193
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred Stock	0	1
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred Stock	$ 4	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Stockholders' equity:
Preferred stock, shares authorized (in shares)	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.10
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	4,304,425	2,166,898
Common stock, shares outstanding (in shares)	4,304,425	2,166,898
Series B Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	6,000
Preferred stock, shares outstanding (in shares)	0	6,000
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Series C Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	36,182	0
Preferred stock, shares outstanding (in shares)	36,182	0
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS [Abstract]
Revenues	$ 31,449	$ 30,707
Cost of revenues	13,498	12,636
Gross profit	17,951	18,071
Operating expenses:
Engineering and product development	1,711	1,929
Selling and marketing	11,249	12,102
General and administrative	7,401	7,637
Total operating expenses	20,361	21,668
Loss from operations	(2,410)	(3,597)
Other income (expense), net:
Interest expense, net	(4,612)	(4,900)
Change in fair value of warrant liability	102	5,396
Other income, net	17	21
Loss on extinguishment of debentures	(11,799)	0
Other income (expense), net	(16,292)	517
Loss before income taxes	(18,702)	(3,080)
Income tax expense	129	255
Net loss	$ (18,831)	$ (3,335)
Net loss per common share:
Basic (in dollars per share)	$ (2.85)	$ (1.57)
Diluted (in dollars per share)	$ (2.85)	$ (3.77)
Shares used in computing net loss per common share:
Basic (in shares)	2,713,782	2,119,014
Diluted (in shares)	2,713,782	2,315,715
Net loss per Preferred C share - basic and diluted (in dollars per share)	$ (1,061.25)	$ 0
Shares used in computing net loss per basic and diluted Preferred C share (in shares)	10,444	0
Other comprehensive (loss) income:
Foreign currency translation adjustments	$ (2)	$ 1
Comprehensive loss	$ (18,833)	$ (3,334)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total	Series C Convertible Preferred Stock [Member]
Beginning balance at Dec. 31, 2015	$ 1	$ 0	$ 2	$ 223,323	$ (207,240)	$ 1	$ 16,087
Beginning balance (in shares) at Dec. 31, 2015	6,505	0	2,056,679
Stock-based compensation	$ 0	$ 0	$ 0	113	0	0	113
Conversion of convertible preferred stock into common stock	$ 0	$ 0	$ 0	0	0	0	0
Conversion of convertible preferred stock into common stock (in shares)	(505)	0	39,337
Conversion of senior secured convertible debentures into common stock	$ 0	$ 0	$ 0	265	0	0	265
Conversion of senior secured convertible debentures into common stock (in shares)	0	0	70,882
Warrants issued in connection with debt	$ 0	$ 0	$ 0	47	0	0	47
Reclassification of warrant liability to stockholders' equity	0	0	0	1,541	0	0	1,541
Other comprehensive income (loss)	0	0	0	0	0	1	1
Net loss	0	0	0	0	(3,335)	0	(3,335)
Ending balance at Dec. 31, 2016	$ 1	$ 0	$ 2	225,289	(210,575)	2	14,719
Ending balance (in shares) at Dec. 31, 2016	6,000	0	2,166,898
Stock-based compensation	$ 0	$ 0	$ 0	186	0	0	186
Issuance of convertible preferred stock in exchange for convertible debentures	$ 0	$ 4	$ 0	25,906	0	0	25,910
Issuance of convertible preferred stock in exchange for convertible debentures (in shares)	0	40,482	0
Conversion of convertible preferred stock into common stock	$ (1)	$ 0	$ 2	0	0	0	1
Conversion of convertible preferred stock into common stock (in shares)	(6,000)	(4,300)	2,066,182
Conversion of senior secured convertible debentures into common stock	$ 0	$ 0	$ 0	262	0	0	262
Conversion of senior secured convertible debentures into common stock (in shares)	0	0	70,000
Issuance of common stock for fractional shares in reverse stock split (in shares)			1,345
Other comprehensive income (loss)						(2)	(2)
Net loss	$ 0	$ 0	$ 0	0	(18,831)	0	(18,831)	$ (11,084)
Ending balance at Dec. 31, 2017	$ 0	$ 4	$ 4	$ 251,643	$ (229,406)	$ 0	$ 22,245
Ending balance (in shares) at Dec. 31, 2017	0	36,182	4,304,425

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows From Operating Activities:
Net loss	$ (18,831)	$ (3,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,336	6,366
Provision for doubtful accounts	109	120
Gain on cancelation of distributor rights agreement	(40)	0
Impairment of lasers placed-in-service	196	0
Impairment of intangible assets	523	0
Stock-based compensation	186	113
Deferred taxes	55	240
Loss on disposal of property and equipment	0	124
Loss on extinguishment of debentures	11,799	0
Amortization of debt discount	2,360	2,473
Amortization of deferred financing costs	188	200
Change in fair value of warrant liability	(102)	(5,396)
Changes in operating assets and liabilities:
Accounts receivable	184	558
Inventories	(193)	1,311
Prepaid expenses and other assets	475	224
Accounts payable	381	(2,605)
Other accrued liabilities	298	(169)
Other liabilities	159	36
Deferred revenues	57	62
Net cash provided by operating activities	4,140	322
Cash Flows From Investing Activities:
Lasers placed-in-service, net	(1,739)	(1,008)
Purchases of property and equipment, net	(320)	0
Payments on distributor rights liability	(135)	0
Restricted cash	0	15
Return of acquisition purchase price from escrow	0	125
Net cash used in investing activities	(2,194)	(868)
Cash Flows From Financing Activities:
Proceeds from long-term debt	0	1,500
Repayments of long-term debt	(1,429)	0
Payments on notes payable	(374)	(333)
Net cash (used in) provided by financing activities	(1,803)	1,167
Effect of exchange rate changes on cash	(2)	4
Net increase in cash and cash equivalents	141	625
Cash and cash equivalents, beginning of period	3,928	3,303
Cash and cash equivalents, end of period	4,069	3,928
Supplemental information:
Cash paid for interest	2,215	2,054
Cash paid for income taxes	28	15
Supplemental information of non-cash investing and financing activities:
Conversion of senior secured convertible debentures into common stock	262	265
Reclassification of warrant liability to stockholders' equity	0	1,541
Recognition of warrants issued with term note credit facility as debt discount	0	47
Prepaid insurance financed with notes payable	392	372
Acquisition of distributor rights asset for license liability	286	0
Issuance of convertible Preferred C stock in exchange for convertible debentures	$ 25,910	$ 0

The Company

12 Months Ended

Dec. 31, 2017

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences, Inc. (and its subsidiary in India) ("STRATA" or "we" or the "Company") is a medical technology company focused on the therapeutic and aesthetic dermatology market. STRATA sales include the following products: XTRAC^® laser and VTRAC^® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN^® MicroSystem, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000. As of December 31, 2017, there were 753 XTRAC systems placed in dermatologists' offices in the United States under the Company's recurring revenue business model. The XTRAC systems employed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment for an agreed upon period not to exceed an agreed upon number of treatments. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer which includes system maintenance, and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.

Effective March 1, 2017, the Company entered into an agreement to license the exclusive US distribution rights for the Ellipse family of products, Nordlys, from Ellipse USA ("Ellipse") through December 31, 2019. The agreement was to be renewed if certain minimum purchase requirements were achieved and an approximate $33 monthly license fee was paid, for a contractual total license fee of $1.1 million over the Initial Term. On October 26, 2017, by mutual agreement of the three parties involved in the transaction, the Company, Ellipse USA and the manufacturer Ellipse A/S, cancelled the agreement with Ellipse USA retroactively effective to August 9, 2017, and the Company entered into two new agreements. Under the new agreements the Company will have the exclusive US distribution rights for the Ellipse family of products, Nordlys, from Ellipse A/S, the Danish manufacturer, through August 9, 2020. If certain sales targets are met, the new agreement will automatically be extended for two additional years. Under the terms of the new agreements, the Company will be the exclusive US distributor of Ellipse lasers and will pay to Ellipse USA a monthly license fee of $10 through August 9, 2020, in addition to commissions for each system sold. The license fee amounts to approximately $355 over the Initial Term with a present value as of the effective date of the agreement of $286. As a result of the termination of the old agreement and the signing of the new agreements the Company reversed the intangible asset and corresponding liability recorded on March 1, 2017 (which resulted in a $40 gain) and recorded the distribution rights at the present value of the payments under the new agreements. See Note 5, Intangible Assets, net, for additional information.

Effective February 1, 2017, the Company entered into an exclusive OEM distribution agreement with Esthetic Education, LLC to be the exclusive marketer and seller of private label versions of the SkinStylus MicroSystem and associated parts under the name of STRATAPen. This three-year agreement allows for two one-year extensions.

Effective April 6, 2017, the Company completed a reverse stock split of its common stock at a ratio of 1-for-5 shares, and all data on common stock and equivalents was retroactively adjusted to be shown herein as reflective of this reverse stock split.

Basis of Presentation:

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company's equity, net assets, results of operations or cash flows.

Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of December 31, 2017, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of intangible assets and goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets (6) the fair value of financial instruments, including derivative instruments, and (7) the inventory reserves.

Revenue Recognition

In the Dermatology Recurring Procedures Segment the Company has two types of arrangements for its phototherapy treatment equipment as follows: (i) the Company places its lasers in a physician's office at no charge to the physician, and generally charges the physician a fee for an agreed upon number of treatments; or (ii) the Company places its lasers in a physician's office and charges the physician a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if number is exceeded additional fees will have to be paid.

For the purposes of U.S. GAAP only, these two types of arrangements are treated as short term operating leases. While these are not contractually operating leases these are viewed as operating leases for accounting purposes since in these arrangements the Company provides the customers the rights to use the treatment equipment and the customers control physical access to the treatment equipment while controlling the utility and output of such equipment during the term of the arrangement. For the first type of arrangement, fees are recognized as revenue over the contract term, which equates to the usage period of the agreed upon number of treatments, as the treatments are being used. For the second type of arrangement fees are recognized as revenue ratably on a straight line basis over the term period specified in the agreement. Contingent amounts that will be paid only if customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Pre-paid amounts are recorded in deferred revenue and recognized as revenue over the lease term in the patterns described above.

The fee charged is inclusive of the use of the system and the services provided by the Company to the customer which include system maintenance and other services. The Company considers the other service and support elements in the contract to be perfunctory and inconsequential.

In the Dermatology Procedures Equipment segment the Company sells its products internationally through a distributor, and domestically directly to a physician. For the product sales, the Company recognizes revenues when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for expected returns and cash discounts.

The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.

The Company records co-pay reimbursements made to patients receiving laser treatments as a reduction of revenue. For the year ended December 31, 2016 the Company reclassified such reimbursements in the amount of $1,050 from selling and marketing expenses to revenues. The Company has determined that such reclassification did not have a material impact to the consolidated financial statements, quantitatively and qualitatively.

Cash and Cash Equivalents

The Company invests its excess cash in highly liquid short-term investments and credit card transactions with settlement terms of less than five days. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Proceeds due from credit card transactions were $353 and $60 as of December 31, 2017 and 2016, respectively. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2017 and 2016.

Accounts Receivable

The majority of the Company's accounts receivable are due from physicians, distributors (international) and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company's previous loss history, the customer's current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the bad debt expense. The Company does not recognize interest accruing on accounts receivable past due. The allowance for doubtful accounts was $172 and $135 at December 31, 2017 and 2016, respectively.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company's products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

The Company's equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends. As of December 31, 2017 and 2016, reserves on inventory were $234 and $257, respectively.

Property, Equipment and Depreciation

Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations and comprehensive loss. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.

Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to ten years. (See Note 5, Intangible Assets, net).

Accounting for the Impairment of Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit's carrying amount exceeds its fair value, referred to as a "step zero" approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. Under Accounting Standards Update ("ASU") 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment," Step 2 from the goodwill impairment test has been eliminated and goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. Early application is permitted. No goodwill impairment was identified in the years ended December 31, 2017 and 2016.

Impairment of Long-Lived Assets and Intangibles

Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted cash flows attributable to the asset. If the carrying amount of an asset exceeds its undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value.

Functional Currency

The currency of the primary economic environment in which the operations of the Company are conducted is the US dollar ("$" or "dollars"). Substantially all of the Company's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.

For foreign currency transactions, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates are carried to financing income or expenses.

Assets and liabilities of the foreign subsidiary, whose functional currency is its local currency are translated from its functional currency to U.S. dollars at the balance sheet date exchange rate. Income and expense items are translated at the average rate of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income.

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the asset or liability and only used when there is little, if any, market activity for the asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2017 and 2016 are as follows:

	Fair Value as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	3	$	-	$	-	$	3

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	105	$	-	$	-	$	105

The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the fair value of the Company's common stock as well as assumptions for volatility, remaining expected life, and the risk-free interest rate. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. As of December 31, 2017, the Company assessed its long-term debt (including the current portion) and determined that the fair value of total debt approximated its book value due to the rate on the debt being at market. As of December 31, 2016, the Company assessed its convertible debentures and long-term debt and determined that the fair value of total debt was $20,082.

Several of the warrants outstanding as of December 31, 2017 and 2016 have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company. Prior to December 31, 2016,other warrants contained full ratchet provisions that would reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the existing exercise price of the warrants. All such warrants are classified as derivatives. As such they are recorded at their fair value using a binomial option pricing model and continue to be recorded at their respective fair value at each subsequent balance sheet date until such terms expire. See Note 11, Warrants, for additional discussion.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the years ended December 31, 2017 and 2016 is summarized as follows:

	December 31,
	2017			2016

Accrual at beginning of year	$	115		$	226
Additions charged to warranty expense		161			196
Expiring warranties/claimed satisfied		(98	)		(307	)
Total		178			115
Less: current portion		(109	)		(102	)
Total long-term accrued warranty costs	$	69		$	13

Product Development Costs

Costs of research, new product development and product redesign are charged to expenses as incurred in engineering and product development in the accompanying consolidated statements of operations and comprehensive loss.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $1,434 and $3,339 for the years ended December 31, 2017 and 2016, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not" to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not" threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions.

Concentration of Credit Risks

Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company deposits cash and cash equivalents in major financial institutions in the US. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs an ongoing credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers (see also Accounts receivable above).

With the exception of the Company's international distributor, as described in Note 17, Significant Customer Concentrations, the balance of the Company's trade receivables do not represent a substantial concentration of credit risk. Most of the Company's sales are generated in North America, to a large number of customers.

Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.

Earnings Per Share

The Company calculates net income (loss) per share in accordance with ASC 260, Earnings per Share. Under ASC 260, basic net income (loss) per common share is calculated by dividing net income by the weighted-average number of common shares outstanding during the reporting period and excludes dilution for potentially dilutive securities. Diluted earnings per share gives effect to dilutive options, warrants and other potential common shares outstanding during the period.

The Company's Series C Preferred Shares are subordinate to all other securities at the same subordination level as common stock and they participate in all dividends and distributions declared or paid with respect to common stock of the Company, on an as-converted basis. Therefore, the Series C Preferred Shares meet the definition of common stock under ASC 260. Earnings per share is presented for each class of security meeting the definition of common stock. The net loss is allocated to each class of security meeting the definition of common stock based on their contractual terms.

The following table presents the calculation of basic and diluted net loss per share by each class of security for the year ended December 31, 2017:

	Year ended December 31, 2017
	Common stock	Series C Preferred stock

Net loss	($ 7,747)	($ 11,084)

Weighted average number of shares outstanding during the period	2,713,782	10,444

Basic and Diluted net loss per share	($ 2.85)	($ 1,061.25)

For the year ended December 31, 2017, diluted net loss per common share and Series C Preferred share is equal to the basic net loss per common share and Series C Preferred share, respectively, since all potentially dilutive securities are anti-dilutive. The gain on the change in fair value of the warrant liability was considered when calculating the diluted earnings per share and was deemed to be antidilutive.

For the year ended December 31, 2016 diluted earnings per common share are computed by the numerator effected by the gain on the change in fair value of the warrant liability and the denominator is increased to include the number of additional potential common shares from the warrants underlying the warrant liability.

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

		Year Ended December 31, 2016

Net loss		($ 3,335)
Gain on the change in fair value of the warrant liability		(5,396)
Diluted loss		($ 8,731)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		2,119,014
Dilutive effect of warrants		196,701
Diluted number of common and common stock equivalent shares outstanding		2,315,715

The weighted average of potential common stock equivalents outstanding during the years ended December 31, 2017 and 2016 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

		Year Ended December 31,
	2017		2016
Common stock equivalents of convertible debentures	6,622,821		9,231,570
Common stock purchase warrants	2,406,625		3,739,037
Common stock equivalents of convertible Preferred B stock	289,462		496,824
Common stock options	876,373		613,773
Total	10,195,281		14,081,204

The convertible debenture shares, warrant shares (except for those related to the gain during the year ended December 31, 2016) and option shares were excluded from net loss per dilutive share because their effect would have been anti-dilutive for the years ended December 31, 2017 and 2016.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as operating expense over the requisite service period of the stock award on a straight line basis. Performance-based awards are recognized only when it is probable that the vesting conditions will be met.

Adoption of New Accounting Standards

In January 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under the current guidance, there are three elements of business: inputs, processes, and outputs. While an integrated set of assets and activities (collectively, a "set") that is a business usually has outputs, outputs are not required to be present. In addition, all the inputs and processes that a seller uses in operating a set are not required if market participants can acquire the set and continue to produce outputs, for example, by integrating the acquired set with their own inputs and processes. The new guidance provides a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. For public business entities, the guidance is effective prospectively for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, but can be adopted early. The Company has adopted this ASU effective January 1, 2017 and has applied the rules with its sub-distribution license with Ellipse and concluded that this transaction did not meet the definition of a business. As such, it has been accounted for as an asset acquisition. See Note 5, Intangible Assets, net.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), to simplify various aspects of the accounting and presentation of share-based payments, including the income tax effects of awards and forfeiture assumptions. The new guidance permits to elect to account for forfeitures as they occur. The Company has made this election upon the adoption of this standard. The guidance became effective for interim and annual periods beginning after December 15, 2016. The adoption of this ASU did not have a significant impact on the consolidated financial statements.

In July 2015, The FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements.

Recently Issued Accounting Standards

In July 2017, the FASB issued a two-part ASU 2017-11, "(Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception." For public business entities, the amendments in Part 1 of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The amendments in Part 2 of ASU 2017-11 do not require any transition guidance because those amendments do not have an accounting effect. The Company is currently evaluating the impact of this guidance on the Company's consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance eliminated Step 2 from the goodwill impairment test which was required in computing the implied fair value of goodwill. Instead, under the new amendments, an entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. If applicable, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The amendments in this guidance are effective for public business entities for annual and interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017. As the Company has not identified a goodwill impairment loss, currently this guidance does not have an impact on the Company's financial statements.

In February 2016 the FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the balance sheet. Under ASU 2016-02, lessees will be required to recognize for all leases with terms longer than 12 months, at the commencement date of the lease, a lease liability, which is a lessee's obligation to make lease payments arising from a lease measured on a discounted basis, and a right-to-use asset, which is an asset that represents the lessee's right to use or control the use of a specified asset for the lease term. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition. Also, the new standard aligns many of the underlying principles of the new lessor model with those in ASC 606, the FASB's new revenue recognition model. The update is Effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. While we continue to evaluate the effect of adopting this guidance on our consolidated financial statements and related disclosures, we expect our operating leases, as disclosed in Note 10, will be subject to the new standard. We will recognize right-of-use assets and operating lease liabilities on our consolidated balance sheets upon adoption, which will increase our total assets and liabilities. With regard to the Company's revenue from short-term leases, we do not expect the new standard to have a material impact on our consolidated financial statements.

In May 2014, The FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company will adopt this ASU effective January 1, 2018 using the modified retrospective method with a cumulative adjustment that will increase its accumulated deficit by approximately $195. The cumulative adjustment will primarily relate to the promise to provide service type warranties related to sales of dermatology procedures equipment. A portion of the transaction price of equipment sold with these service type warranties will be allocated to such warranties based on their stand-alone selling price, and the Company will begin to recognize revenue from these service type warranties ratably over the warranty term. Under current guidance only separately priced extended warranties are required to be accounted for as separate elements and be recognized over the warranty term. Other than the above change related to warranties the Company does not expect the standard to have a material impact on its financial condition or results of operations.

Liquidity and Going Concern	12 Months Ended
Liquidity and Going Concern	Dec. 31, 2017
Liquidity and Going Concern [Abstract]
Liquidity and Going Concern	Note 2 Liquidity and Going Concern: As of December 31, 2017, the Company had an accumulated deficit of $229,406 and had been incurring losses since inception through 2017 as well as negative cash flows from operations until 2016. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses. On March 30, 2018 the Company entered into a Stock Purchase Agreement (the "Accelmed SPA") with Accelmed Growth Partners ("Accelmed"), pursuant to which Accelmed has agreed to invest $13,000 into the Company in exchange for 12,037,037 shares of the Company's common stock at a per share purchase price of $1.08. In connection with the proposed Accelmed investment, the Company entered into two separate stock purchase agreements on March 30, 2018 for $1,000 each with our current shareholders, Broadfin Capital ("Broadfin") and Sabby Management ("Sabby"). Upon closing of these transactions, each of Sabby and Broadfin will receive 925,926 shares of the Company's common stock at a per share purchase price of $1.08. Two separate subscription agreements were also executed on March 30, 2018 for $1,000 each to purchase 925,926 shares of our common stock at a per share purchase price of $1.08. In addition, Sabby and Broadfin have entered into a voting undertaking with the Company pursuant to which each of them has agreed (a) to increase their respective ownership interest to 9.99% of the outstanding shares of Company's common stock prior to the record date for the meeting of the shareholders, and (b) vote all their voting shares in the Company at the meeting to approve the proposed transaction. See Note 18 – Subsequent Events for additional detail. While management believes that its current cash and cash equivalents as of December 31, 2017, combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, and capital asset purchases, for the next 12 months following the filing of this form 10-K, there is a risk associated with the Company's ability to meet its debt obligations should the Company breach its debt covenants during 2018. The current MidCap agreement has financial covenants including a minimum monthly net revenue covenant. If the Company fails to meet the revenue covenant, it may be declared in breach of the credit facility agreement, and Midcap would have the option to call the full debt balance outstanding under the credit facility agreement, which was $10,240 as of December 31, 2017. The Company has 30 days to report a default and upon notice from Midcap of a financial covenant breach, the Company has an additional 10 business days to cure such default. The Company, however, cannot be certain that this default will be cured in such period or at all. In connection with the proposed investment led by Accelmed, the Company entered into a non-binding letter of intent dated March 30, 2018 with Midcap Financial Trust ("MidCap") pursuant to which the Company and MidCap will agree to terminate the Company's existing Midcap credit facility agreement and replace it with a new credit facility agreement with MidCap. This new credit facility agreement is contingent upon $14,000 in new equity financing and the repayment of $3,000 on the current facility upon closing of the equity financing transactions described above. The equity financings described in this footnote are subject to shareholder approval. Therefore, there is uncertainty whether the Company will close on the equity purchase and subscription agreements as well as the MidCap non-binding letter of intent. While there is no guarantee of shareholder approval, management is confident that shareholders will reach both a quorum and a positive vote since Sabby and Broadfin, per the voting agreement described above, have proposed to increase their respective blockers to a combined 19.99% of the vote.

Property and Equipment, net

12 Months Ended

Dec. 31, 2017

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 4

Property and Equipment, net:

	December 31, 2017			December 31, 2016

Lasers placed-in-service	$	17,820		$	16,712
Equipment, computer hardware and software		462			160
Furniture and fixtures		124			111
Leasehold improvements		31			25
		18,437			17,008
Accumulated depreciation and amortization		(10,734	)		(6,828	)
Property and equipment, net	$	7,703		$	10,180

Depreciation and related amortization expense was $4,341 and $4,551 for the year ended December 31, 2017 and 2016, respectively. During the year ended December 31, 2017, the Company recorded an impairment loss of $196 to cost of revenues related to lasers placed-in-service at the Company's subsidiary in India. During the year ended December 31, 2016, the Company disposed of leasehold improvements, machinery and equipment and furniture and fixtures with a recorded cost of $3,933 and accumulated depreciation and amortization of $3,809, related to the closing of its Irvington, New York facility. The net book value of $124 was written off to general and administrative expense.

Intangible Assets, net

12 Months Ended

Dec. 31, 2017

Intangible Assets, net [Abstract]

Intangible Assets, net

Note 5

Intangible Assets, net:

	December 31, 2017			December 31, 2016

Core technology	$	5,700		$	5,974
Product technology		1,500			2,000
Customer relationships		6,900			6,900
Tradenames		1,500			1,500
Distribution rights		286			-
		15,886			16,374
Accumulated amortization		(4,561	)		(2,962	)
Intangible assets, net	$	11,325		$	13,412

Related amortization expense was $1,995 and $1,815 for each of the years ended December 31, 2017 and 2016.

During the year ended December 31, 2017, the Company wrote off core technology of $274 and accumulated amortization of $251 related to the discontinuance of the MELAfind product. The value written off of $23 was recorded in cost of revenues.

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company recognizes an impairment loss when and to the extent that the recoverable amount of an intangible asset is less than its carrying value. For the year ended December 31, 2017 the Company recognized a total of $500 of intangible asset impairment charges with respect to product technology, which were recognized as cost of revenues charges on the Company's consolidated statement of operations and comprehensive loss. The impairment charge equals the excess of the carrying value over the asset's fair value. The fair value of the product technology was determined based on Level 3 inputs, which included estimated revenues attributable to product technology, discount and growth rates, as well royalty rates acceptable in the market.

As discussed in Note 1, effective January 1, 2017 the Company follows the guidance in ASU 2017-01, which provides a new framework for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under the new guidance, companies are required to utilize an initial screening test to determine whether substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the asset is not a business. The Company has determined that its transaction with Ellipse in the first quarter of 2017 is considered to be an acquisition of a single asset, therefore, the acquisition is not considered to be an acquisition of a business. The distribution rights asset had been assigned a value of $900 which was comprised of the present value of the license fee payments. Effective August 2017 the transaction was terminated and a new agreement was negotiated among the parties. See Note 1 for further details regarding these agreements. As a result of the termination of the old agreement and the signing of the new agreements the Company reversed the intangible asset and corresponding liability recorded on March 1, 2017 and recorded the distribution rights at the present value of the payments under the new agreements, amounting to $286. The reversal of the aforementioned intangible asset and corresponding liability resulted in a $40 gain that was recognized in sales and marketing expense.

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2018	$	1,905
2019		1,605
2020		1,470
2021		1,410
2022		1,410
Thereafter		3,525
Total	$	11,325

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2017

Other Accrued Liabilities [Abstract]

Other Accrued Liabilities

Note 7

Other Accrued Liabilities:

	December 31, 2017		December 31, 2016

Accrued warranty, current, see Note 1	$	109	$	102
Accrued compensation, including commissions and vacation		785		1,177
Accrued sales and other taxes		904		439
Distributor rights liability, current		85		-
Accrued professional fees and other accrued liabilities		477		274
Total other accrued liabilities	$	2,360	$	1,992

Included in accrued sales and other taxes are certain estimated sales and use taxes and related penalties and interest to taxing authorities. The Company has been subject to audits performed by the taxing authorities. The Company uses estimates when accruing its sales and use tax liability, including interest and penalties. All of the Company's tax positions are subject to audit. While the Company believes all of its estimates and assumptions are reasonable and will be sustained upon audit, actual liabilities and credits may differ significantly. The Company believes its accruals cover all probable payments relating to sales and use taxes.

Convertible Debentures

12 Months Ended

Dec. 31, 2017

Convertible Debentures [Abstract]

Convertible Debentures

Note 8

Convertible Debentures:

In the following table is a summary of the Company's convertible debentures.

	December 31, 2016

Senior secured 2.25% convertible debentures, net of unamortized debt discount of $24,314; and deferred financing costs of $524	$	7,174
Senior secured 4% convertible debentures, net of unamortized debt discount of $3,469; and deferred financing costs of $392		4,854
Total convertible debt	$	12,028

The total outstanding convertible debentures was exchanged for convertible Preferred C stock on September 20, 2017, thus there was no remaining outstanding balance as of December 31, 2017.

The Company issued $32,500 aggregate principal amount of Debentures (the "June 2015 Debentures") that, subject to certain ownership limitations and stockholder approval conditions, was convertible into 8,666,668 shares of Company common stock at an initial conversion price of $3.75 per share. The Debentures were bearing interest at the rate of 2.25% per year, and, unless previously converted, were to mature on the five-year anniversary of the date of issuance, June 22, 2020.

The June 2015 Debentures included a beneficial conversion feature valued at $27,300 that was recorded as a discount to the debentures. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $3.75 from $6.90, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures were convertible. This discount was being amortized over the five year life of the June 2015 Debentures using the effective interest method. The embedded conversion feature contained an anti-dilution provision that allowed for downward exercise price adjustments in certain situations. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 1,239,769 shares of common stock, $0.001 par value per share, at an exercise price of $12.25 per share expiring in July 2019.

The July 2014 Debentures were bearing interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures were convertible at any time into an aggregate of 1,169,595 shares of common stock at an initial conversion price of $12.825 per share. The Company's obligations under the July 2014 Debentures were secured by a first priority lien on all of the Company's intellectual property pursuant to the terms of a security agreement ("Security Agreement") dated July 21, 2014 among the Company and the Investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (See Note 11, Warrants) and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249).

For financial reporting purposes, out of the $15,000 funded by the Investors on July 21, 2014 $5,296 was allocated first to the Warrants issued, then $4,565 to the intrinsic value of the beneficial conversion feature on the July 2014 Debentures. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the July 2014 Debentures totaled $10,353 and was being amortized using the effective interest method over the five year life of the July 2014 Debentures.

During the year ended December 31, 2017, the investors converted June 2015 Debentures amounting to $262 into 70,000 shares of common stock. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $197 for the year ended December 31, 2017.

As a condition of the new note facility (See Note 9, Long-term Debt) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021 and treated as a modification.

On June 6, 2017, the Company entered into a Securities Exchange Agreement (the "Agreement") with the holders of its 2.25% Senior Series A Secured Convertible Debentures due June 30, 2021 and 4% Senior Secured Convertible Debentures due June 30, 2021, pursuant to which the holders have agreed to exchange all of such outstanding debentures into shares of newly created Series C Convertible Preferred Stock. The stockholders approved the exchange at the stockholders' meeting held on September 14, 2017. The closing of the exchange was effective on September 20, 2017 and $40,465 of principal was exchanged for 40,482 shares of Series C Preferred Stock. In accordance with ASC Topic 470, Debt, the aforementioned exchange was treated as an extinguishment of debt. As there was no intrinsic value for the conversion feature on the date of extinguishment, none of the proceeds were allocated to the extinguishment of the beneficial conversion feature. As such, the difference between the fair value of the convertible preferred stock issued (determined based on the market value of the underlying common stock) and the net carrying value of the convertible debentures of $11,799 was recognized as a loss on extinguishment of debentures.

Other than the limitations on conversions to keep each such holders beneficial ownership below 9.99%, the terms of the Series C Convertible Preferred Stock generally bestow the same rights to each holder as such holder would receive if they are common stock shareholder and are not redeemable by the holders, except the Series C Convertible Preferred Stock shares do not have voting rights. The Series C Convertible Preferred Stock have the same level of subordination as common stock. Each share of Series C Convertible Preferred Stock has a stated value of $1,000 and is convertible into 372 shares of common stock (at a conversion price equal to $2.69) for a total of approximately 15,049,000 shares of common stock.

Total interest expense related to these convertible debentures was $3,117 and $3,525 for the years ended December 31, 2017 and 2016, respectively.

Long-term Debt

12 Months Ended

Dec. 31, 2017

Long-term Debt [Abstract]

Long-term Debt

Note 9

Long-term Debt:

	December 31, 2017			December 31, 2016

Term note, net of debt discount of $160 and $258, respectively; and deferred financing cost of $171 and $276, respectively	$	10,240		$	11,466
Less: current portion		(2,387	)		(1,714	)
Total long-term debt	$	7,853		$	9,752

Term-Note Credit Facility

On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Agreement") and related financing documents with MidCap Financial Trust ("MidCap") and the lenders listed therein. Under the Agreement, the credit facility may be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The proceeds of this first tranche were used to repay $10,000 principal amount of short-term senior secured promissory notes, plus associated interest, loan fees and expenses. The second tranche was drawn for $1,500 on January 29, 2016. The Company's obligations under the credit facility are secured by a first priority lien on all of the Company's assets. This credit facility includes both financial and non-financial covenants, including a minimum net revenue covenant, beginning in January 2016. On November 10, 2017, the minimum net revenue covenant was amended prospectively. Additionally on November 10, 2017, the Company entered into an amendment to modify the principal payments including a period of six months where there are no principal payments due. The interest rate on the credit facility is one month LIBOR plus 8.25%, subject to a LIBOR floor of 0.5% (9.61% as of December 31, 2017). On March 26, 2018, the Company further amended the minimum net revenue covenant retrospectively to the closing date of the loan in order for the Company to be in compliance with these covenants as of December 31, 2017. Refer to Note 18 Subsequent Events for additional detail.

Warrants to purchase shares of the Company's common stock that were issued in connection with the credit facility resulted in a discount to the debt. The discount is accreted using the effective interest rate method over the repayment term.

The following table summarizes the future payments that the Company is obligated to make for the long-term debt for the future periods:

2018	$	2,387
2019		4,092
2020		4,092
	$	10,571

Warrants

12 Months Ended

Dec. 31, 2017

Warrants [Abstract]

Warrants

Note 11

Warrants:

The Company accounts for warrants that require net cash settlement upon change of control of the Company as liabilities instead of equity. Currently there are 403,090 of such warrants with an exercise price of $3.75 per share and they expire between February 5, 2019 and April 30, 2019.

The Company recognizes these liabilities at the fair value on each reporting date. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2017 and December 31, 2016 is as follows:

	December 31, 2017			December 31, 2016

Number of shares underlying the warrants		403,090			403,090
Stock price	$	1.23		$	2.20
Volatility		48.60	%		47.00	%
Risk-free interest rate		1.76	%		1.22	%
Expected dividend yield		0	%		0	%
Expected warrant life	1.12 – 1.35 years			2.12 – 2.35 years

Recurring Level 3 Activity and Reconciliation

The tables below provide a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3).

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	December 31, 2016		Decrease in Fair Value			December 31, 2017

10/31/2013	$	39	$	(37	)	$	2
2/5/2014		66		( 65	)		1

Total	$	105	$	(102	)	$	3

Issuance Date	December 31, 2015		Decrease in Fair Value			Reclassification to Equity			December 31, 2016

10/31/2013	$	379	$	(340	)	$	-		$	39
2/5/2014		715		(649	)		-			66
7/24/2014 Series A		2,415		(1,573	)		(842	)		-
7/24/2014 Series B		1,726		(1,713	)		(13	)		-
6/22/2015		1,807		(1,121	)		(686	)		-

Total	$	7,042	$	(5,396	)	$	(1,541	)	$	105

Number of Warrants Subject to Remeasurement:

	Issuance Date	December 31, 2017

	10/31/2013	137,143
	2/5/2014	265,947

	Total	403,090

Stockholders' Equity

12 Months Ended

Dec. 31, 2017

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 12

Stockholders' Equity:

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors. There were 36,182 and 0 shares of Series C convertible preferred stock issued and outstanding on December 31, 2017 and 2016, respectively, and there were 0 and 6,000 shares of Series B convertible preferred stock issued and outstanding on December 31, 2017 and 2016, respectively.

Other than the limitations on conversions to keep each such holders beneficial ownership below 9.99%, the terms of the Series C Convertible Preferred Stock generally bestow the same rights to each holder as such holder would receive if they are common stock shareholder and are not redeemable by the holders, except that the Series C Convertible Preferred Stock shares do not have voting rights. The Series C Convertible Preferred Stock have the same level of subordination as common stock. Each share of Series C Convertible Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69 for a total of approximately 15,049,000 shares of common stock.

During October 2017, investors converted Series C Preferred Stock into 1,598,346 shares of common stock.

Common Stock and Warrants

The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.001 per share. There were 4,304,425 and 2,166,898 issued and outstanding at December 31, 2017 and 2016, respectively.

Outstanding common stock warrants at December 31, 2017 consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		13,865	$	55.90
10/31/2013*	4/30/2019		137,143	$	3.75
2/5/2014*	2/5/2019		265,947	$	3.75
7/24/2014	7/24/2019		1,239,769	$	3.75 - $ 12.25
6/22/2015	6/22/2020		600,000	$	3.75
12/30/2015	12/30/2020		130,089	$	5.65
1/29/2016	1/29/2021		19,812	$	5.30
			2,406,625

*These warrants are classified as liabilities (See Note 11, Warrants).

Stock-based compensation

12 Months Ended

Dec. 31, 2017

Stock-based compensation [Abstract]

Stock-based compensation

Note 13

Stock-based compensation:

Stock Options

On October 27, 2016, the Company's stockholders approved the Company's adoption of the new 2016 Omnibus Incentive Stock Plan ("2016 Plan") having 2,058,880 shares available for issuance in respect of awards made thereunder. The Company terminated the 2013 Stock Incentive Plan in October 2016. As of December 31, 2017, the aggregate number of shares of common stock remaining available for issuance for awards under the 2016 Plan totaled 1,624,795.

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2017 and 2016 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2015		536,904		$	8.07
Granted		468,002			2.90
Exercised		-			-
Expired/forfeited		(104,767	)		10.35
Outstanding at December 31, 2016		900,139			5.11
Granted		101,250			1.46
Exercised		-			-
Expired/forfeited		(135,667	)		4.78
Outstanding at December 31, 2017		865,722		$	4.74
Exercisable at December 31, 2017		542,905		$	6.10
Options expected to vest at December 31, 2017		188,484		$	2.24

The outstanding and exercisable options at December 31, 2017, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Avg. Exercise Price
$	1.29 - $5.00		483,585		8.90	$	2.58		160,867	$	2.90
$	5.01 - $10.00		372,500		7.62		6.19		372,500		6.19
$	10.01 - $181.00		9,637		5.44		56.65		9,538		56.35
Total			865,722		8.31	$	4.74		542,905	$	6.10

The weighted average remaining contractual life of exercisable options was 7.84 years and 7.56 years at December 31, 2017 and 2016, respectively.

As the share price as of December 31, 2017 was $1.23, the aggregate intrinsic value for options outstanding and exercisable was $0.

Stock awards under the Company's stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the plans are generally time-based or performance-based options and vesting varies accordingly (see below for specific vesting conditions). Options under the plans expire up to a maximum of ten years from the date of grant. The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2017	2016
Risk-free interest rate	1.98 – 2.17%	1.51 – 2.18%
Volatility	46%-48%	50%
Expected dividend yield	0%	0%
Expected life	5.5 years	6.5 years
Estimated forfeiture rate	0%	0%

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Volatility is based on the Company's historical stock prices matching the expected term of the award. The risk-free rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

On December 6, 2016, the Company granted an aggregate of 90,000 options to purchase common stock to the board directors with a strike price of $2.75. The options vested over a one year period and expire ten years from the date of grant. The aggregate fair value of the options granted was $127.

On October 31, 2016, the Company issued 108,501 options to purchase common stock to its Chief Executive Officer with a strike price of $2.75. The options vest over three years and expire ten years from the date of grant. The aggregate fair value of the options granted was $150. Additionally, the Company issued 201,501 options to purchase common stock to its Chief Executive Officer with a strike price of $2.75. These options vest based on performance goals determined by the board of directors for each of the years 2017 through 2019. The aggregate fair value of the options granted was $279. The 67,167 options associated with 2017 performance goals were forfeited effective December 31, 2017 as the goals were not met, and it is not probable that the performance goals for 2018 and 2019 will be met. Accordingly, no compensation expense has been recorded for these performance-based options.

On June 7, 2016, the Company granted an aggregate of 68,000 options to purchase common stock to a number of employees with a strike price of $3.75. The options vest over four years and expire ten years from the date of grant. The aggregate fair value of the options granted was $128.

On May 10, 2017 the Company granted 11,250 options to purchase common stock to a new board director with a strike price of $2.78. The options vested during 2017 and expire ten years from the date of grant. The aggregate fair value of the options granted was $14.

On December 1, 2017, The Company granted an aggregate of 90,000 options to purchase common stock to the board directors with a strike price of $1.29. The options vest over a one year period and expire ten years from the date of grant. The aggregate fair value of the options granted was $54.

Stock-based compensation expense, which is included in general and administrative expense, for the years ended December 31, 2017 and 2016 was $186 and $113, respectively. As of December 31, 2017 there was $190 in unrecognized compensation expense, which will be recognized over a weighted average period of 1 year.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

Income Taxes

Note 14

Income Taxes:

	Year Ended December 31,
	2017			2016
Current:
Federal	$	64		$	-
State		11			15
		75			15
Deferred:
Federal		(24	)		178
State		78			62
		54			240

Income tax expense	$	129		$	255

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from net operating loss carryforwards and temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is not more likely than not that a tax benefit will be realized.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; creating a new limitation on deductible interest expense; changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and limitations on the deductibility of certain executive compensation.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 ("SAB 118"), which addresses situations where the accounting is incomplete for the income tax effects of the Act. SAB 118 directs taxpayers to consider the impact of the Act as "provisional" when the Company does not have the necessary information available, prepared or analyzed (including computations) to finalize the accounting for the change in tax law. Companies are provided a measurement period of up to one year to obtain, prepare, and analyze information necessary to finalize the accounting for provisional amounts or amounts that cannot be estimated as of December 31, 2017.

With regards to the Tax Act impact on the tax provision as it relates to the Company for the year ended December 31, 2017, we have recognized the provisional impact of tax reform related to the revaluation of deferred tax assets and liabilities from 35% to 21% of $23.8 million tax expense, which is almost entirely offset by a reduction in the valuation allowance.

With regards to the one-time transition tax, we did not record any tax liability as we estimate that the accumulated earnings and profits of our foreign subsidiary will be in a deficit position. Because of the complexity of the new international tax provisions included in the Act that are not applicable to the Company until 2018, the Company is continuing to evaluate these provisions of the Act and the application of ASC 740.

We will continue to refine our calculations as additional analysis is completed related to the Act. Additional information that may affect our provisional amounts would include further clarification and guidance on how the IRS will implement tax reform, including guidance with respect to the above, further clarification and guidance on how state taxing authorities will implement tax reform and the related effect on our state income tax returns, completion of our 2017 tax return filings, and the potential for additional guidance from the SEC or the FASB related to tax reform.

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2017			2016

Computed expected tax benefit	$	(6,359	)	$	(1,047	)
State tax benefit, net of federal effect		(1,113	)		(499	)
Warrant value fluctuation		(34	)		(1,835	)
Tax Cuts and Jobs Act impact		23,834			-
Net (decrease) increase in valuation allowance		(16,199	)		3,636
Provision for income taxes	$	129		$	255

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2017 and 2016 are as follows:

	December 31,
	2017			2016

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	50,472		$	72,870
Intangible assets		4,595			8,711
Inventory		66			149
Reserves & accrued expenses		228			291
Convertible debt discount		-			(11,097	)
Property & equipment		130			432
Non-cash compensation		793			1,127
Goodwill		(414	)		(359	)
Total deferred tax assets		55,870			72,124
Less: valuation allowance		(56,284	)		(72,483	)
Net deferred tax assets/(liabilities)	$	(414	)	$	(359	)

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company's historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2017 and 2016. The Company's valuation allowance against its deferred tax assets decreased by $16,199 for the year ended December 31, 2017.

At December 31, 2017 and 2016, the Company has federal net operating loss carryforwards of approximately $181,413 and $183,658, respectively, to offset future taxable income. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company's ability to utilize its net operating losses in the future. The February 2014, July 2014 and June 2015 equity raises by the Company, will likely limit the annual use of these net operating loss carryforwards. Although the Company has not performed a Section 382 study, any limitation of its pre-change net operating loss carryforwards that would result in a reduction of its deferred tax asset would also have an equal and offsetting adjustment to the valuation allowance.

FASB ASC 740 "Income Taxes" contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

The Company does not have any uncertain tax positions or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The company's tax years are still under open status from 2014 to present. All open years may be examined to the extent that net operating loss carryforward are used in future periods.

Business Segments and Geographic Data

12 Months Ended

Dec. 31, 2017

Business Segments and Geographic Data [Abstract]

Business Segments and Geographic Data

Note 15

Business Segments and Geographic Data:

The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generated revenues from the sale and usage of imaging devices. The Company has announced that it will no longer support the imaging devices effective September 30, 2017 thus there will be minimal continuing revenues for this segment. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2017

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	22,640		$	8,792		$	17		$	31,449
Costs of revenues		8,744			4,529			225			13,498
Gross profit		13,896			4,263			(208	)		17,951
Gross profit %		61.4	%		48.5	%		-1223.5	%		57.1	%

Allocated operating expenses:
Engineering and product development		1,431			279			1			1,711
Selling and marketing expenses		9,454			1,795			0			11,249

Unallocated operating expenses		-			-			-			7,401
		10,885			2,074			1			20,361
Income (loss) from operations		3,011			2,189			(209	)		(2,410	)

Interest expense, net		-			-			-			(4,612	)
Change in fair value of warrant liability		-			-			-			102
Other income (expense), net		-			-			-			17
Loss on extinguishment of debentures		-			-			-			(11,799	)

Income (loss) before income taxes	$	3,011		$	2,189		$	(209	)	$	(18,702	)

Year Ended December 31, 2016

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	23,508		$	7,065		$	134		$	30,707
Costs of revenues		8,763			3,506			367			12,636
Gross profit		14,745			3,559			(233	)		18,071
Gross profit %		62.7	%		50.4	%		(173.9	%)		58.8	%

Allocated operating expenses:
Engineering and product development		1,288			210			431			1,929
Selling and marketing expenses		11,541			375			186			12,102

Unallocated operating expenses		-			-			-			7,637
		12,829			585			617			21,668
Income (loss) from operations		1,916			2,974			(850	)		(3,597	)

Interest expense, net		-			-			-			(4,900	)
Change in fair value of warrant liability		-			-			-			5,396
Other income (expense), net		-			-			-			21

Income (loss) before income taxes	$	1,916		$	2,974		$	(850	)	$	(3,080	)

For the year ended December 31, 2017 and 2016 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2017		2016
Domestic	$	26,178	$	24,486
Foreign		5,271		6,221
	$	31,449	$	30,707

As of December 31, 2017 and 2016, total assets by reportable segment were as follows:

	December 31,
Assets:	2017		2016
Dermatology Recurring Procedures	$	29,722	$	34,612
Dermatology Procedures Equipment		4,403		3,980
Dermatology Imaging		-		265
Other unallocated assets		4,506		4,336
Consolidated total	$	38,631	$	43,193

Substantially all long lived assets were located in domestic markets for both of the years ended December 31, 2017 and 2016.

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2017
Related Parties [Abstract]
Related Parties	Note 16 Related Parties: On June 22, 2015, the Company entered into a securities purchase agreement with the Purchasers, including certain funds managed by Sabby Management, LLC and Broadfin Capital LLC (existing Company shareholders), in connection with a private placement. The Purchasers were issued Warrants to purchase an aggregate of 0.6 million shares of common stock, having an exercise price of $3.75 per share. We also issued $32.5 million aggregate principal amount of Debentures that, subject to certain ownership limitations and stockholder approval conditions, were convertible into 8,666,668 shares of common stock at an initial conversion price of $3.75 per share. The Debentures were bearing interest at the rate of 2.25% per year, and, unless previously converted, were to mature on the five-year anniversary of the date of issuance. Refer to Note 8 for additional information on the terms of the Debentures and for information on the interest expense relating to the Debentures. On September 30, 2015, the Company repriced outstanding Warrants held by certain investors to reduce the exercise price to $3.75 per share. On June 6, 2017, the Company entered into a Securities Exchange Agreement (the "Agreement") with the holders of its 2.25% Senior Series A Secured Convertible Debentures due June 30, 2021 and 4% Senior Secured Convertible Debentures due July 30, 2021, pursuant to which the holders have agreed to exchange all of such outstanding debentures into shares of newly created Series C Convertible Preferred Stock. The stockholders approved the exchange at the stockholders' meeting held on September 14, 2017. The closing of the exchange was effective on September 20, 2017 and $40,465 of principal was exchanged for 40,482 shares of Series C Preferred Stock. In accordance with ASC Topic 470, Debt, the aforementioned exchange was treated as an extinguishment of debt. As there was no intrinsic value for the conversion feature on the date of extinguishment, none of the proceeds were allocated to the extinguishment of the beneficial conversion feature. As such, the difference between the fair value of the convertible preferred stock issued (determined based on the market value of the underlying common stock) and the net carrying value of the convertible debentures (adjusted for unamortized premium discount), of $11,799 was recognized as a loss on extinguishment of debentures. See Note 12 for additional information on Series C Convertible Preferred Stock. On November 4, 2015, the Company entered into consulting agreements with two of its directors, Jeffrey F. O'Donnell, Sr. and Samuel E. Navarro, the terms of which are the same. Under the terms of their respective agreements, each director agrees to provide strategic support, advice and guidance to the Company and its management team in connection with the integration and operation of the expanded business, investor relations and internal and external business development activities. The consultant will make himself available to the Company's President and Chief Executive Officer and the management team on request at mutually convenient times and will report to the Board of Directors quarterly and otherwise when requested by the Board. The agreements had been extended through June 30 and December 31, 2017 for Mr. Navarro and Mr. O'Donnell, respectively. The directors were each to be paid an up-front fee of $40 for advice and services rendered prior to the date of the agreement, including advice related to the acquisition of the XTRAC and VTRAC assets and the structuring of the financing for that acquisition, a retainer of $10 per month, commencing November 10, 2015 and continuing on the tenth day of each month through the expiration of their respective agreements, and reimbursement of pre-approved, out-of-pocket expenses. The agreements expired per their terms on June 30, 2017 and December 31, 2017, respectively, and no extensions or renewals of the agreement were entered into. The Company expensed $180 and $240 related to these agreements during the years ended December 31, 2017 and 2016, respectively. These amounts are included in general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. During 2017, Modevity LLC ("Modevity"), the developer of the ARALOC Secure Content Distribution Platform, a software system for sharing proprietary and / or confidential content files over the internet and allowing its users to collaborate securely from any mobile or desktop device, has provided certain consulting services to the Company advising on the development of our digital media and marketing initiatives, including providing assistance in our first limited test of targeted advertising using Facebook. Our Board member, James Coyne, has been the Chief Executive Officer of Modevity since helping to found the company in April 2004. To date, Modevity has provided this assistance without charge to the Company. Independent of these services provided by Modevity, in November 2017 the Company entered into an agreement with Olympic Media, a company founded by Ryan Coyne, the son of James Coyne, to create and execute a focused tactical plan to leverage new and existing digital assets across social and digital platforms to drive psoriasis and vitiligo sufferers to the Company's website and call center for conversion to new patient appointments. The agreement with Olympic Media provides for no minimum payments or other financial commitments and is terminable by either party without penalty on ten days written notice. During December 2017, the Company made a $30 payment to Olympic Media. James Coyne has no financial interest in Olympic Media.

Significant Customer Concentration	12 Months Ended
Significant Customer Concentration	Dec. 31, 2017
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 17 Significant Customer Concentration: For the year ended December 31, 2017, revenues from sales to the Company's international master distributor (GlobalMed Technologies) were $5,264, or 16.7%, of total revenues for such period. At December 31, 2017, the accounts receivable balance from GlobalMed Technologies was $475, or 15.1%, of total net accounts receivable. For the year ended December 31, 2016, revenues from sales to the Company's international master distributor were $6,093, or 19.8% of total revenues for such period. No other customer represented more than 10% of total company revenues for the year ended December 31, 2017 and 2016. No other customer represented more than 10% of total accounts receivable as of December 31, 2017.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 18 Subsequent Events: Series C Preferred Stock Conversion During January 2018, investors converted Series C Preferred Stock into 75,000 shares of common stock. Third Amendment – MidCap Credit and Security Agreement On March 26, 2018 we entered into a Third Amendment to Credit and Security Agreement with Midcap. For the period beginning on the Closing Date and ending on January 31, 2018, the gross revenue in accordance with GAAP for the twelve-month period ending on the last day of the most recently completed calendar month was amended to be less than the minimum amount on the Covenant Schedule. The Amendment waives the event of default related to the revenue covenant for period ending February 2018. The Amendment also amends a monthly net revenue covenant for March and April 2018. MidCap Non-binding Letter of Intent In connection with the proposed investment led by Accelmed Growth Partners L.P. ("Accelmed") described below, we entered into a non-binding letter of intent dated March 30, 2018 with Midcap to terminate the existing Midcap loan agreement and replace it with a new agreement. This new agreement is contingent upon our raising $14,000 in new equity financing and the repayment of $3,000 on the current facility. Under the new agreement among other terms, the base amount of the loan is to be $7,571; the term is for 48 months; interest only payments for the first 18 months; and straight-line principal payments for the remaining 30 months. This loan will be collateralized by substantially all the assets of the Company and will contain certain financial and non-financial covenants. Stock Purchase and Subscription Agreements Accelmed Stock Purchase Agreement On March 30, 2018 we entered into a Stock Purchase Agreement (the "Accelmed SPA") and a Registration Rights Agreement with Accelmed investing $13,000 into the Company at a price per share of $1.08, upon closing Accelmed will receive 12,037,037shares of our common stock. The Company may incur additional expenses, or Acclemed may receive additional shares in the event of certain contingencies. The Company is required to reimburse Accelmed for its legal, consulting, due diligence and administrative costs related to the proposed stock purchase, including the reasonable legal fees, disbursements and related charges of Accelmed's counsel in an aggregate amount not to exceed $400 (or up to $500 in the event of certain contingencies, and subject to no cap in the event the Company's stockholders do not approve the transaction) at the earliest of (i) the closing, or (ii) the termination of Accelmed SPA for any reason other than by reason of a breach of the Accelmed SPA by Accelmed. The Company may also be obligated to pay a breakup fee of $600 in the event the Company's board of directors makes a recommendation against the approval of the transaction. The Accelmed SPA also requires that the Company indemnify Accelmed for certain items as defined in SPA. In connection with the Accelmed investment, the Company has agreed to pay a fee equal to 4% of the amount paid at closing to HC Wainwright, the Company's placement agent. This fee is in addition to the fees that will be owed to Fairmount Partners, the Company's financial advisor. Upon the closing of the Accelmed transaction, the Company is obligated to pay Fairmount Partners a fee of $680 of which $100 has been paid as a retainer, leaving a balance to be paid at closing of $580. In the event the Company becomes obligated to pay additional investment advisors fees, the Company is obligated to indemnify Accelmed for the additional payment. Broadfin Capital and Sabby Management Stock Purchase Agreements In connection with the proposed Accelmed investment, we entered into two separate stock purchase agreements on March 30, 2018, each for approximately $1,000 with our current shareholders, Broadfin Capital ("Broadfin") and Sabby Management ("Sabby"). Upon closing of these transactions, each of Sabby and Broadfin will receive 925,926 shares of our common stock at a price per share of $1.08. In further consideration of entering into their respective stock purchase agreements, Sabby and Broadfin have each entered into separate agreements restricting their abilities to sell their holdings (the "Leak-Out Agreements"). Under the terms of each of the respective Leak-Out Agreements, the stockholder has agreed that from the later of (a) the date that the approval by the shareholders of the transactions and deemed effective and (b) the closing of the transactions contemplated pursuant to the SPA, the stockholder shall not sell dispose or otherwise transfer, directly or indirectly, (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent to any sales or short positions) any shares of Common Stock of the Company held by the Stockholder on the date hereof or issuable to the Stockholder upon conversion of shares of the Company's Preferred Stock held by the Stockholder on the date hereof, (a) if prior to April 1, 2019, at a price per Company Share less than $1.296, subject to adjustment for reverse and forward stock splits and the like, or (b) thereafter, at a price per share reflecting less than the price set forth on the schedule in the Leak-Out Agreements subject to adjustment for reverse and forward stock splits and the like, unless, (1) in the case of either clauses (a) or (b), otherwise approved by the Company's Board of Directors, (2) in the case of either clause (b), under a shelf prospectus or such other controlled offering as may be agreed to by the Principal Stockholders (as defined in the Stock Purchase Agreement) or (3) in the case of either clauses (a) or (b), in a sale pursuant to which any other stockholder(s) of the Company are offered the same terms of sale, including in a merger, consolidation, transfer or conversion involving the Company or any of its subsidiaries. Subscription Agreements Two separate subscription agreements were also executed on March 30, 2018 in connection with the Accelmed investment: (i) a subscription agreement with Gohan Investments, Ltd. for $1,000 to purchase 925,926 shares of our common stock at $1.08 per share; and (ii) a subscription agreement with Dr. Dolev Rafaeli for $1,000 to purchase 925,926 shares of our common stock at $1.08 per share. Change in Executive Leadership and Board Members Pursuant to the Accelmed SPA, on April 10, 2018, we will have a change in administration by which, Dr. Dolev Rafaeli will become Interim Chief Executive Officer and Frank J McCaney, our current CEO, will become Interim Chief Financial Officer. Additionally, effective after the closing of the investment at least five of the current board members will resign Accelmed shall have the right to fill all the remaining vacancies effective as of the Closing. The Company intends to schedule a special meeting of the shareholders as soon as practical and within the time limits set forth in the Accelmed SPA.

The Company (Policies)

12 Months Ended

Dec. 31, 2017

The Company [Abstract]

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

Reclassification

Use of Estimates

Revenue Recognition

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Equipment and Depreciation

Intangible Assets

Accounting for the Impairment of Goodwill

Impairment of Long-Lived Assets and Intangibles

Functional Currency

Fair Value Measurements

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the asset or liability and only used when there is little, if any, market activity for the asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2017 and 2016 are as follows:

	Fair Value as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	3	$	-	$	-	$	3

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	105	$	-	$	-	$	105

Accrued Warranty Costs

	December 31,
	2017			2016

Accrual at beginning of year	$	115		$	226
Additions charged to warranty expense		161			196
Expiring warranties/claimed satisfied		(98	)		(307	)
Total		178			115
Less: current portion		(109	)		(102	)
Total long-term accrued warranty costs	$	69		$	13

Product Development Costs

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $1,434 and $3,339 for the years ended December 31, 2017 and 2016, respectively.

Income Taxes

Concentration of Credit Risks

Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts.

Earnings Per Share

The following table presents the calculation of basic and diluted net loss per share by each class of security for the year ended December 31, 2017:

	Year ended December 31, 2017
	Common stock	Series C Preferred stock

Net loss	($ 7,747)	($ 11,084)

Weighted average number of shares outstanding during the period	2,713,782	10,444

Basic and Diluted net loss per share	($ 2.85)	($ 1,061.25)

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

		Year Ended December 31, 2016

Net loss		($ 3,335)
Gain on the change in fair value of the warrant liability		(5,396)
Diluted loss		($ 8,731)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		2,119,014
Dilutive effect of warrants		196,701
Diluted number of common and common stock equivalent shares outstanding		2,315,715

		Year Ended December 31,
	2017		2016
Common stock equivalents of convertible debentures	6,622,821		9,231,570
Common stock purchase warrants	2,406,625		3,739,037
Common stock equivalents of convertible Preferred B stock	289,462		496,824
Common stock options	876,373		613,773
Total	10,195,281		14,081,204

Stock-Based Compensation

Adoption of New Accounting Standards

Recently Issued Accounting Standards

The Company (Tables)

12 Months Ended

Dec. 31, 2017

The Company [Abstract]

Fair Value Measurements on Recurring Basis

The Company's recurring fair value measurements at December 31, 2017 and 2016 are as follows:

	Fair Value as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	3	$	-	$	-	$	3

	Fair Value as of December 31, 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	105	$	-	$	-	$	105

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2017 and 2016 is summarized as follows:

	December 31,
	2017			2016

Accrual at beginning of year	$	115		$	226
Additions charged to warranty expense		161			196
Expiring warranties/claimed satisfied		(98	)		(307	)
Total		178			115
Less: current portion		(109	)		(102	)
Total long-term accrued warranty costs	$	69		$	13

Calculation of Basic and Diluted Net Loss Per Share by Class of Security

The following table presents the calculation of basic and diluted net loss per share by each class of security for the year ended December 31, 2017:

	Year ended December 31, 2017
	Common stock	Series C Preferred stock

Net loss	($ 7,747)	($ 11,084)

Weighted average number of shares outstanding during the period	2,713,782	10,444

Basic and Diluted net loss per share	($ 2.85)	($ 1,061.25)

Diluted Earnings Per Common Share Calculated Using Net Loss and Weighted Average Shares Outstanding

Diluted earnings per common share were calculated using the following net loss and weighted average shares outstanding for the year ended December 31, 2016:

		Year Ended December 31, 2016

Net loss		($ 3,335)
Gain on the change in fair value of the warrant liability		(5,396)
Diluted loss		($ 8,731)

Weighted average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		2,119,014
Dilutive effect of warrants		196,701
Diluted number of common and common stock equivalent shares outstanding		2,315,715

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

		Year Ended December 31,
	2017		2016
Common stock equivalents of convertible debentures	6,622,821		9,231,570
Common stock purchase warrants	2,406,625		3,739,037
Common stock equivalents of convertible Preferred B stock	289,462		496,824
Common stock options	876,373		613,773
Total	10,195,281		14,081,204

Inventories (Tables)

12 Months Ended

Dec. 31, 2017

Inventories [Abstract]

Schedule of Inventory

	December 31, 2017		December 31, 2016

Raw materials and work in progress	$	2,490	$	2,440
Finished goods		519		377
	$	3,009	$	2,817

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2017

Property and Equipment, net [Abstract]

Summary of Property and Equipment, Net

	December 31, 2017			December 31, 2016

Lasers placed-in-service	$	17,820		$	16,712
Equipment, computer hardware and software		462			160
Furniture and fixtures		124			111
Leasehold improvements		31			25
		18,437			17,008
Accumulated depreciation and amortization		(10,734	)		(6,828	)
Property and equipment, net	$	7,703		$	10,180

Intangible Assets, net (Tables)

12 Months Ended

Dec. 31, 2017

Intangible Assets, net [Abstract]

Schedule of Definite-lived Intangible Assets

	December 31, 2017			December 31, 2016

Core technology	$	5,700		$	5,974
Product technology		1,500			2,000
Customer relationships		6,900			6,900
Tradenames		1,500			1,500
Distribution rights		286			-
		15,886			16,374
Accumulated amortization		(4,561	)		(2,962	)
Intangible assets, net	$	11,325		$	13,412

Finite-lived Intangible Assets Amortization Expense

2018	$	1,905
2019		1,605
2020		1,470
2021		1,410
2022		1,410
Thereafter		3,525
Total	$	11,325

Goodwill (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill Disclosure [Abstract]

Schedule of Goodwill

Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to identifiable tangible and intangible assets. Goodwill is not amortized, but is reviewed annually for impairment. Goodwill was recorded on the acquisition of the XTRAC and VTRAC businesses on June 22, 2015 as the purchase price exceeded the fair value of the identifiable net assets of the business.

Balance at January 1, 2016	$	8,928
Return of purchase price from escrow		(125	)
Balance at December 31, 2016 and 2017	$	8,803

The Company has no accumulated impairment losses of goodwill as of December 31, 2017.

The goodwill was allocated among the reportable segments in accordance with the provisions of ASC Topic 350-20 and consisted of the following:

	December 31, 2017 and 2016

Dermatology Recurring Procedures segment	$	7,958
Dermatology Procedures Equipment segment		845
Total	$	8,803

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2017

Long-term Debt [Abstract]

Long-term Debt

	December 31, 2017			December 31, 2016

Term note, net of debt discount of $160 and $258, respectively; and deferred financing cost of $171 and $276, respectively	$	10,240		$	11,466
Less: current portion		(2,387	)		(1,714	)
Total long-term debt	$	7,853		$	9,752

Summary of Maturities of Long-term Debt

The following table summarizes the future payments that the Company is obligated to make for the long-term debt for the future periods:

2018	$	2,387
2019		4,092
2020		4,092
	$	10,571

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Warrants (Tables)

12 Months Ended

Dec. 31, 2017

Warrants [Abstract]

Warrants Fair Value Assumptions

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2017 and December 31, 2016 is as follows:

	December 31, 2017			December 31, 2016

Number of shares underlying the warrants		403,090			403,090
Stock price	$	1.23		$	2.20
Volatility		48.60	%		47.00	%
Risk-free interest rate		1.76	%		1.22	%
Expected dividend yield		0	%		0	%
Expected warrant life	1.12 – 1.35 years			2.12 – 2.35 years

Schedule of Fair Value Hierarchy

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	December 31, 2016		Decrease in Fair Value			December 31, 2017

10/31/2013	$	39	$	(37	)	$	2
2/5/2014		66		( 65	)		1

Total	$	105	$	(102	)	$	3

Issuance Date	December 31, 2015		Decrease in Fair Value			Reclassification to Equity			December 31, 2016

10/31/2013	$	379	$	(340	)	$	-		$	39
2/5/2014		715		(649	)		-			66
7/24/2014 Series A		2,415		(1,573	)		(842	)		-
7/24/2014 Series B		1,726		(1,713	)		(13	)		-
6/22/2015		1,807		(1,121	)		(686	)		-

Total	$	7,042	$	(5,396	)	$	(1,541	)	$	105

Schedule of Warrants Subject to Remeasurement

Number of Warrants Subject to Remeasurement:

	Issuance Date	December 31, 2017

	10/31/2013	137,143
	2/5/2014	265,947

	Total	403,090

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders' Equity [Abstract]

Summary of Outstanding Common Stock Warrants

Outstanding common stock warrants at December 31, 2017 consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		13,865	$	55.90
10/31/2013*	4/30/2019		137,143	$	3.75
2/5/2014*	2/5/2019		265,947	$	3.75
7/24/2014	7/24/2019		1,239,769	$	3.75 - $ 12.25
6/22/2015	6/22/2020		600,000	$	3.75
12/30/2015	12/30/2020		130,089	$	5.65
1/29/2016	1/29/2021		19,812	$	5.30
			2,406,625

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2017

Stock-based compensation [Abstract]

Schedule of Stock Option Plans

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2017 and 2016 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2015		536,904		$	8.07
Granted		468,002			2.90
Exercised		-			-
Expired/forfeited		(104,767	)		10.35
Outstanding at December 31, 2016		900,139			5.11
Granted		101,250			1.46
Exercised		-			-
Expired/forfeited		(135,667	)		4.78
Outstanding at December 31, 2017		865,722		$	4.74
Exercisable at December 31, 2017		542,905		$	6.10
Options expected to vest at December 31, 2017		188,484		$	2.24

Schedule of Stock Options Outstanding and Exercisable

The outstanding and exercisable options at December 31, 2017, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices		Outstanding Number of Shares		Weighted Average Remaining Contractual Life (years)		Weighted Average Exercise Price		Exercisable Number of Shares		Exercisable Weighted Avg. Exercise Price
$	1.29 - $5.00		483,585		8.90	$	2.58		160,867	$	2.90
$	5.01 - $10.00		372,500		7.62		6.19		372,500		6.19
$	10.01 - $181.00		9,637		5.44		56.65		9,538		56.35
Total			865,722		8.31	$	4.74		542,905	$	6.10

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2017	2016
Risk-free interest rate	1.98 – 2.17%	1.51 – 2.18%
Volatility	46%-48%	50%
Expected dividend yield	0%	0%
Expected life	5.5 years	6.5 years
Estimated forfeiture rate	0%	0%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

Components of Income Tax Expense

	Year Ended December 31,
	2017			2016
Current:
Federal	$	64		$	-
State		11			15
		75			15
Deferred:
Federal		(24	)		178
State		78			62
		54			240

Income tax expense	$	129		$	255

Computation of U.S. Federal Income Tax Rate to Pretax Loss from Continuing Operations

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2017			2016

Computed expected tax benefit	$	(6,359	)	$	(1,047	)
State tax benefit, net of federal effect		(1,113	)		(499	)
Warrant value fluctuation		(34	)		(1,835	)
Tax Cuts and Jobs Act impact		23,834			-
Net (decrease) increase in valuation allowance		(16,199	)		3,636
Provision for income taxes	$	129		$	255

Summary of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2017 and 2016 are as follows:

	December 31,
	2017			2016

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	50,472		$	72,870
Intangible assets		4,595			8,711
Inventory		66			149
Reserves & accrued expenses		228			291
Convertible debt discount		-			(11,097	)
Property & equipment		130			432
Non-cash compensation		793			1,127
Goodwill		(414	)		(359	)
Total deferred tax assets		55,870			72,124
Less: valuation allowance		(56,284	)		(72,483	)
Net deferred tax assets/(liabilities)	$	(414	)	$	(359	)

Business Segments and Geographic Data (Tables)

12 Months Ended

Dec. 31, 2017

Business Segments and Geographic Data [Abstract]

Schedule of Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2017

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	22,640		$	8,792		$	17		$	31,449
Costs of revenues		8,744			4,529			225			13,498
Gross profit		13,896			4,263			(208	)		17,951
Gross profit %		61.4	%		48.5	%		-1223.5	%		57.1	%

Allocated operating expenses:
Engineering and product development		1,431			279			1			1,711
Selling and marketing expenses		9,454			1,795			0			11,249

Unallocated operating expenses		-			-			-			7,401
		10,885			2,074			1			20,361
Income (loss) from operations		3,011			2,189			(209	)		(2,410	)

Interest expense, net		-			-			-			(4,612	)
Change in fair value of warrant liability		-			-			-			102
Other income (expense), net		-			-			-			17
Loss on extinguishment of debentures		-			-			-			(11,799	)

Income (loss) before income taxes	$	3,011		$	2,189		$	(209	)	$	(18,702	)

Year Ended December 31, 2016

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	23,508		$	7,065		$	134		$	30,707
Costs of revenues		8,763			3,506			367			12,636
Gross profit		14,745			3,559			(233	)		18,071
Gross profit %		62.7	%		50.4	%		(173.9	%)		58.8	%

Allocated operating expenses:
Engineering and product development		1,288			210			431			1,929
Selling and marketing expenses		11,541			375			186			12,102

Unallocated operating expenses		-			-			-			7,637
		12,829			585			617			21,668
Income (loss) from operations		1,916			2,974			(850	)		(3,597	)

Interest expense, net		-			-			-			(4,900	)
Change in fair value of warrant liability		-			-			-			5,396
Other income (expense), net		-			-			-			21

Income (loss) before income taxes	$	1,916		$	2,974		$	(850	)	$	(3,080	)

Schedule of Net Revenues by Geographic Areas

For the year ended December 31, 2017 and 2016 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2017		2016
Domestic	$	26,178	$	24,486
Foreign		5,271		6,221
	$	31,449	$	30,707

Summary of Total Assets by Reportable Segment

As of December 31, 2017 and 2016, total assets by reportable segment were as follows:

	December 31,
Assets:	2017		2016
Dermatology Recurring Procedures	$	29,722	$	34,612
Dermatology Procedures Equipment		4,403		3,980
Dermatology Imaging		-		265
Other unallocated assets		4,506		4,336
Consolidated total	$	38,631	$	43,193

The Company (Details) $ / shares in Units, $ in Thousands		12 Months Ended
The Company (Details) $ / shares in Units, $ in Thousands	Apr. 06, 2017	Dec. 31, 2017 USD ($) Systems Party Agreement Extension Arrangement $ / shares shares	Dec. 31, 2016 USD ($) shares	Mar. 31, 2017 USD ($)
Business Acquisition [Line Items]
Intangible assets, gross		$ 15,886	$ 16,374
Reverse stock-split ratio	0.20
Cash and Cash Equivalents [Line Items]
Proceeds due from credit card transactions		$ 353	60
Revenue Recognition [Abstract]
Number of types of arrangements \| Arrangement		2
Revenue reimbursements			1,050
Accounts Receivable, Net [Abstract]
Allowance for doubtful accounts		$ 172	135
Inventories [Abstract]
Reserves on inventory		234	257
Accounting for the Impairment of Goodwill [Abstract]
Goodwill impairment		0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt			20,082
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss		(18,831)	(3,335)
Product Warranty Accrual [Roll Forward]
Accrual at beginning of year		115	226
Additions charged to warranty expense		161	196
Expiring warranties/claimed satisfied		(98)	(307)
Total		178	115
Less: current portion		(109)	(102)
Total long-term accrued warranty costs		69	13
Earnings Per Share [Abstract]
Net loss			(3,335)
Gain on the change in fair value of the warrant liability		$ (102)	(5,396)
Diluted loss			$ (8,731)
Weighted average number of common and common equivalent shares outstanding [Abstract]
Basic number of common shares outstanding (in shares) \| shares		2,713,782	2,119,014
Dilutive effect of warrants (in shares) \| shares			196,701
Diluted number of common and common stock equivalent shares outstanding (in shares) \| shares		2,713,782	2,315,715
Advertising Costs [Abstract]
Advertising expense		$ 1,434	$ 3,339
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares		10,195,281	14,081,204
Distribution Rights [Member]
Business Acquisition [Line Items]
Intangible assets, gross		$ 286	$ 0
Product Technology [Member]
Business Acquisition [Line Items]
Intangible assets, gross		$ 1,500	2,000
Esthetic Education, LLC [Member]
Business Acquisition [Line Items]
Agreement period		3 years
Number of extensions allowed \| Extension		2
Period of extension		1 year
Ellipse Agreement [Member]
Business Acquisition [Line Items]
Monthly license fee		$ 33
License fee for initial term		$ 1,100
Number of parties involved in transaction \| Party		3
Ellipse New Agreement [Member]
Business Acquisition [Line Items]
Monthly license fee		$ 10
License fee for initial term		$ 355
Number of new agreements \| Agreement		2
License agreement, number of additional years automatically extended		2 years
Ellipse New Agreement [Member] \| Distribution Rights [Member]
Business Acquisition [Line Items]
Intangible assets, gross		$ 286		$ 900
Gain on contract termination		$ 40
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life		3 years
Product Warranty Liability [Line Items]
Standard warranty period		1 year
Offered warranty period		3 years
Maximum [Member]
Cash and Cash Equivalents [Line Items]
Credit card transaction settlement term		5 days
Finite-Lived Intangible Assets [Line Items]
Estimated useful life		10 years
Product Warranty Liability [Line Items]
Standard warranty period		2 years
Offered warranty period		4 years
Excimer Lasers-in-Service [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		5 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		$ 3	105
Fair Value, Measurements, Recurring [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0	0
Fair Value, Measurements, Recurring [Member] \| Significant other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		0	0
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		3	$ 105
Common Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss		$ (7,747)
Weighted average number of shares outstanding during the period (in shares) \| shares		2,713,782
Basic and Diluted net loss per share (in dollars per share) \| $ / shares		$ (2.85)
Series C Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss		$ (11,084)
Weighted average number of shares outstanding during the period (in shares) \| shares		10,444
Basic and Diluted net loss per share (in dollars per share) \| $ / shares		$ (1,061.25)
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices \| Systems		753
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares		6,622,821	9,231,570
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares		2,406,625	3,739,037
Common Stock Equivalents of Convertible Preferred B Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares		289,462	496,824
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares		876,373	613,773
ASU 2014-09 [Member] \| Plan [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase in accumulated deficit		$ 195

Liquidity and Going Concern (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Apr. 10, 2018	Mar. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Liquidity [Abstract]
Accumulated deficit			$ (229,406)	$ (210,575)
Class of Stock [Line Items]
Revenue covenants, cure period in the event of default			30 days
Term-Note Credit Facility [Member]
Class of Stock [Line Items]
Debt balance outstanding under credit facility agreement			$ 10,240	$ 11,466
Subsequent Event [Member] \| Broadfin Capital [Member]
Class of Stock [Line Items]
Percentage of blocker prior to record date for meeting of shareholders	9.99%	9.99%
Subsequent Event [Member] \| Sabby Management [Member]
Class of Stock [Line Items]
Percentage of blocker prior to record date for meeting of shareholders	9.99%	9.99%
Subsequent Event [Member] \| Accelmed Stock Purchase Agreement [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 13,000
Expected equity financing investment (in shares)		12,037,037
Share price (in dollars per share)		$ 1.08
Subsequent Event [Member] \| Broadfin Capital and Sabby Management Stock Purchase Agreements [Member] \| Broadfin Capital [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 1,000
Expected equity financing investment (in shares)		925,926
Share price (in dollars per share)		$ 1.08
Subsequent Event [Member] \| Broadfin Capital and Sabby Management Stock Purchase Agreements [Member] \| Sabby Management [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 1,000
Expected equity financing investment (in shares)		925,926
Share price (in dollars per share)		$ 1.08
Subsequent Event [Member] \| Midcap Non-binding Letter of Intent Agreement [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 14,000
Percentage of blocker prior to record date for meeting of shareholders		19.99%
Repayment on current facility		$ 3,000
Subsequent Event [Member] \| Subscription Agreement [Member] \| Broadfin Capital [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 1,000
Expected equity financing investment (in shares)		925,926
Share price (in dollars per share)		$ 1.08
Subsequent Event [Member] \| Subscription Agreement [Member] \| Sabby Management [Member]
Class of Stock [Line Items]
Expected equity financing investment		$ 1,000
Expected equity financing investment (in shares)		925,926
Share price (in dollars per share)		$ 1.08

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule of inventory [Abstract]
Raw materials and work in progress	$ 2,490	$ 2,440
Finished goods	519	377
Inventories, net	$ 3,009	$ 2,817

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,437	$ 17,008
Accumulated depreciation and amortization	(10,734)	(6,828)
Property and equipment, net	7,703	10,180
Depreciation and related amortization expense	4,341	4,551
Impairment of long-lived assets	(196)
Net book value written off	0	124
Irvington New York facility [Member]
Property, Plant and Equipment [Line Items]
Amount of disposed of leasehold improvements, machinery and equipment and furniture and fixtures		3,933
Amount of accumulated depreciation and amortization		(3,809)
Lasers Placed-In-Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,820	16,712
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	462	160
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	124	111
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 31	$ 25

Intangible Assets, net (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets, net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 15,886	$ 16,374
Accumulated amortization	(4,561)	(2,962)
Intangible assets, net	11,325	13,412
Amortization expense of intangible assets	1,995	1,815
Impairment of intangible assets	523	0
Estimated amortization expense [Abstract]
2018	1,905
2019	1,605
2020	1,470
2021	1,410
2022	1,410
Thereafter	3,525
Intangible assets, net	11,325	13,412
MelaFind Systems [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	23
Write-off of accumulated amortization of discontinued operations	251
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	5,700	5,974
Core Technology [Member] \| MelaFind Systems [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	274
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	1,500	2,000
Impairment of intangible assets	500
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	6,900	6,900
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	1,500	1,500
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	286	$ 0
Distribution Rights [Member] \| Ellipse New Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	286		$ 900
Gain on contract termination	$ 40

Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2017
Goodwill Disclosure [Abstract]
Accumulated impairment losses of goodwill		$ 0
Goodwill [Roll Forward]
Balance at beginning of period	$ 8,928
Return of purchase price from escrow	(125)
Balance at end of period	$ 8,803

Goodwill, Allocated Reported Segments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill	$ 8,803	$ 8,803	$ 8,928
Dermatology Recurring Procedures [Member]
Goodwill [Line Items]
Goodwill	7,958	7,958
Dermatology Procedures Equipment [Member]
Goodwill [Line Items]
Goodwill	$ 845	$ 845

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1	$ 109	$ 102
Accrued compensation, including commissions and vacation	785	1,177
Accrued sales and other taxes	904	439
Distributor rights liability, current	85	0
Accrued professional fees and other accrued liabilities	477	274
Total other accrued liabilities	$ 2,360	$ 1,992

Convertible Debentures (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	Sep. 14, 2017 shares	Jun. 06, 2017 shares $ / shares	Jul. 21, 2014 USD ($) shares $ / shares	Dec. 31, 2017 USD ($) shares $ / shares	Dec. 31, 2016 USD ($) $ / shares	Sep. 13, 2017 USD ($)
Debt Instrument [Line Items]
Total convertible debt				$ 0	$ 12,028
Common stock, par value (in dollars per share) \| $ / shares				$ 0.001	$ 0.001
Change in fair value of warrant liability				$ (102)	$ (5,396)
Debentures converted in shares of common stock, value				262	265
Loss on extinguishment of debentures				$ (11,799)	0
Preferred stock, par value (in dollars per share) \| $ / shares				$ 0.10
Interest expense related to convertible debenture				$ 3,117	$ 3,525
Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt						$ 40,465
Number of shares debt convertible (in shares) \| shares				15,049,000
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares				$ 2.69
Beneficial ownership percentage				9.99%
Preferred stock, par value (in dollars per share) \| $ / shares				$ 0.10	$ 0.10
Senior Secured 2.25% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt					$ 7,174
Debt instrument, unamortized discount					24,314
Deferred financing costs					524
Interest rate				2.25%
Aggregate principal amount of debt				$ 32,500
Number of shares debt convertible (in shares) \| shares				8,666,668
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares				$ 3.75
Maturity period				5 years
Maturity date				Jun. 30, 2021
Debt instrument, convertible, beneficial conversion feature				$ 27,300
Senior Secured 2.25% Convertible Debentures [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares				$ 3.75
Senior Secured 2.25% Convertible Debentures [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares				$ 6.90
Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt					4,854
Debt instrument, unamortized discount			$ 10,353		3,469
Deferred financing costs					$ 392
Interest rate		4.00%		4.00%
Aggregate principal amount of debt			$ 15,000	$ 15,000
Number of shares debt convertible (in shares) \| shares			1,169,595
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares			$ 12.825
Maturity period				5 years
Maturity date				Jun. 30, 2021
Debt instrument, convertible, beneficial conversion feature			$ 4,565
Fair value of warrants			5,296
Change in fair value of warrant liability			491
Debt instrument initial carrying amount			$ 4,647
Debentures converted in shares of common stock, value				$ 262
Debt conversion, converted instrument, issued (in shares) \| shares				70,000
Interest expense on debt				$ 197
Senior Secured 4% Convertible Debentures [Member] \| Series A Warrants [Member]
Debt Instrument [Line Items]
Number of warrants to purchase common stock (in shares) \| shares			1,239,769
Exercise price of warrants (in dollars per share) \| $ / shares			$ 12.25
Common stock, par value (in dollars per share) \| $ / shares			$ 0.001
Warrants expiration date				Jul. 31, 2019
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] \| Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares debt convertible (in shares) \| shares		15,049,000
Senior secured convertible debentures conversion price (in dollars per share) \| $ / shares		$ 2.69
Debt conversion, converted instrument, issued (in shares) \| shares	40,482
Preferred stock, par value (in dollars per share) \| $ / shares		$ 1,000		$ 1,000
Each share of preferred stock to common stock (in shares) \| shares		372
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] \| Series C Convertible Preferred Stock [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Beneficial ownership percentage		9.99%

Long-term Debt (Details) $ in Thousands			12 Months Ended
Long-term Debt (Details) $ in Thousands	Jan. 29, 2016 USD ($)	Dec. 30, 2015 USD ($)	Dec. 31, 2017 USD ($) Tranche	Dec. 31, 2016 USD ($)
Long-term Debt [Abstract]
Less: current portion			$ (2,387)	$ (1,714)
Total long-term debt			7,853	9,752
Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Term note, net of debt discount of $160 and $258, respectively; and deferred financing cost of $171 and $276, respectively			10,240	11,466
Less: current portion			(2,387)	(1,714)
Total long-term debt			7,853	9,752
Unamortized discount on the long term debt			160	258
Deferred financing costs			171	$ 276
Maturities of Long-term Debt [Abstract]
2018			2,387
2019			4,092
2020			4,092
Total long-term debt			10,571
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member]
Long-term Debt [Abstract]
Maximum borrowing capacity under the agreement			$ 12,000
Number of tranches \| Tranche			2
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Debt instrument variable rate			8.25%
Debt instrument term of variable rate			1 month
Interest rate			9.61%
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| LIBOR [Member] \| Minimum [Member]
Long-term Debt [Abstract]
LIBOR floor rate			0.50%
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| First Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility		$ 10,500
Repayment of debt		$ (10,000)
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| Second Tranche [Member]
Long-term Debt [Abstract]
Proceeds from credit facility	$ 1,500

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingencies [Abstract]
Rent expense charged to operations	$ 528	$ 783
Future Annual Minimum Payments under Operating Leases [Abstract]
2018	426
2019	174
2020	14
2021	14
2022	14
Total	$ 642

Warrants (Details) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price of warrants (in dollars per share)	$ 3.75
Fair Value Assumptions [Abstract]
Number of shares underlying warrants (in shares)	403,090	403,090
Share price (in dollars per share)	$ 1.23	$ 2.20
Volatility	48.60%	47.00%
Risk-free interest rate	1.76%	1.22%
Expected dividend yield	0.00%	0.00%
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	403,090
Minimum [Member]
Fair Value Assumptions [Abstract]
Expected warrant life	1 year 1 month 13 days	2 years 1 month 13 days
Maximum [Member]
Fair Value Assumptions [Abstract]
Expected warrant life	1 year 4 months 6 days	2 years 4 months 6 days
10/31/2013 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	137,143
2/5/2014 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]
Number of warrants to purchase common stock (in shares)	265,947
Level 3 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	$ 105	$ 7,042
Decrease in Fair Value	(102)	(5,396)
Reclassification to Equity		(1,541)
Balance as end of period	3	105
Level 3 [Member] \| 10/31/2013 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	39	379
Decrease in Fair Value	(37)	(340)
Reclassification to Equity		0
Balance as end of period	2	39
Level 3 [Member] \| 2/5/2014 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	66	715
Decrease in Fair Value	(65)	(649)
Reclassification to Equity		0
Balance as end of period	1	66
Level 3 [Member] \| 7/24/2014 Series A [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	0	2,415
Decrease in Fair Value		(1,573)
Reclassification to Equity		(842)
Balance as end of period		0
Level 3 [Member] \| 7/24/2014 Series B [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	0	1,726
Decrease in Fair Value		(1,713)
Reclassification to Equity		(13)
Balance as end of period		0
Level 3 [Member] \| 6/22/2015 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period	$ 0	1,807
Decrease in Fair Value		(1,121)
Reclassification to Equity		(686)
Balance as end of period		$ 0

Stockholders' Equity (Details)

1 Months Ended

12 Months Ended

Jun. 06, 2017

$ / shares

Oct. 31, 2017

Dec. 31, 2017

$ / shares

Dec. 31, 2016

$ / shares

Class of Stock [Line Items]

Preferred stock, shares authorized (in shares)

10,000,000

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.10

Common stock, shares authorized (in shares)

150,000,000

Common stock, par value (in dollars per share) | $ / shares

$ 0.001

Common stock, shares issued (in shares)

4,304,425

2,166,898

Common stock, shares outstanding (in shares)

4,304,425

2,166,898

Class of Warrant or Right [Line Items]

Total Warrants (in shares)

2,406,625

Common Stock Warrant One [Member]

Class of Warrant or Right [Line Items]

Issue Date

Apr. 26, 2013

Expiration Date

Apr. 26, 2018

Total Warrants (in shares)

13,865

Exercise price (in dollars per share) | $ / shares

$ 55.90

Common Stock Warrant Two [Member]

Class of Warrant or Right [Line Items]

Issue Date

^[1]

Oct. 31, 2013

Expiration Date

^[1]

Apr. 30, 2019

Total Warrants (in shares)

^[1]

137,143

Exercise price (in dollars per share) | $ / shares

^[1]

$ 3.75

Common Stock Warrant Three [Member]

Class of Warrant or Right [Line Items]

Issue Date

^[1]

Feb. 05, 2014

Expiration Date

^[1]

Feb. 05, 2019

Total Warrants (in shares)

^[1]

265,947

Exercise price (in dollars per share) | $ / shares

^[1]

$ 3.75

Common Stock Warrant Four [Member]

Class of Warrant or Right [Line Items]

Issue Date

Jul. 24, 2014

Expiration Date

Jul. 24, 2019

Total Warrants (in shares)

1,239,769

Common Stock Warrant Four [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Exercise price (in dollars per share) | $ / shares

$ 3.75

Common Stock Warrant Four [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Exercise price (in dollars per share) | $ / shares

$ 12.25

Common Stock Warrant Five [Member]

Class of Warrant or Right [Line Items]

Issue Date

Jun. 22, 2015

Expiration Date

Jun. 22, 2020

Total Warrants (in shares)

600,000

Exercise price (in dollars per share) | $ / shares

$ 3.75

Common Stock Warrant Six [Member]

Class of Warrant or Right [Line Items]

Issue Date

Dec. 30, 2015

Expiration Date

Dec. 30, 2020

Total Warrants (in shares)

130,089

Exercise price (in dollars per share) | $ / shares

$ 5.65

Common Stock Warrant Seven [Member]

Class of Warrant or Right [Line Items]

Issue Date

Jan. 29, 2016

Expiration Date

Jan. 29, 2021

Total Warrants (in shares)

19,812

Exercise price (in dollars per share) | $ / shares

$ 5.30

Series C Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized (in shares)

10,000,000

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.10

Preferred stock, shares issued (in shares)

36,182

Preferred stock, shares outstanding (in shares)

36,182

Beneficial ownership percentage

9.99%

Number of shares debt convertible (in shares)

15,049,000

Number of preferred stock converted (in shares)

1,598,346

Initial stock price (in dollars per share) | $ / shares

$ 2.69

Series C Convertible Preferred Stock [Member] | Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member]

Class of Stock [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 1,000

Number of shares debt convertible (in shares)

15,049,000

Initial stock price (in dollars per share) | $ / shares

$ 2.69

Series C Convertible Preferred Stock [Member] | Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] | Maximum [Member]

Class of Stock [Line Items]

Beneficial ownership percentage

9.99%

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized (in shares)

10,000,000

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.10

Preferred stock, shares issued (in shares)

6,000

Preferred stock, shares outstanding (in shares)

6,000

[1]	These warrants are classified as liabilities (See Note 10, Warrants).

Stock-based compensation (Details) - $ / shares	12 Months Ended
Stock-based compensation (Details) - $ / shares	Dec. 31, 2017	Dec. 31, 2016	Oct. 27, 2016
Stock Options [Member]
Number of Stock Options [Roll Forward]
Outstanding at beginning period (in shares)	900,139	536,904
Granted (in shares)	101,250	468,002
Exercised (in shares)	0	0
Expired/forfeited (in shares)	(135,667)	(104,767)
Outstanding at end of period (in shares)	865,722	900,139
Exercisable at end of period (in shares)	542,905
Options expected to vest at end of period (in shares)	188,484
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 5.11	$ 8.07
Granted (in dollars per share)	1.46	2.90
Exercised (in dollars per share)	0	0
Expired/forfeited (in dollars per share)	4.78	10.35
Outstanding at end of period (in dollars per share)	4.74	$ 5.11
Exercisable at end of period (in dollars per share)	6.10
Options expected to vest at end of period (in dollars per share)	$ 2.24
Stock Incentive Plan 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)	1,624,795		2,058,880

Stock-based compensation, Stock Options Plan by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding number of shares (in shares)	865,722
Weighted average remaining contractual life	8 years 3 months 22 days
Weighted average exercise price (in dollars per share)	$ 4.74
Exercisable number of shares (in shares)	542,905
Exercisable weighted average exercise price (in dollars per share)	$ 6.10
Weighted average remaining contractual life of exercisable stock options	7 years 10 months 2 days	7 years 6 months 22 days
$1.29 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 1.29
Upper range limit (in dollars per share)	$ 5.00
Outstanding number of shares (in shares)	483,585
Weighted average remaining contractual life	8 years 10 months 24 days
Weighted average exercise price (in dollars per share)	$ 2.58
Exercisable number of shares (in shares)	160,867
Exercisable weighted average exercise price (in dollars per share)	$ 2.90
$5.01 - $10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	5.01
Upper range limit (in dollars per share)	$ 10.00
Outstanding number of shares (in shares)	372,500
Weighted average remaining contractual life	7 years 7 months 13 days
Weighted average exercise price (in dollars per share)	$ 6.19
Exercisable number of shares (in shares)	372,500
Exercisable weighted average exercise price (in dollars per share)	$ 6.19
$10.01 - $181.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	10.01
Upper range limit (in dollars per share)	$ 181.00
Outstanding number of shares (in shares)	9,637
Weighted average remaining contractual life	5 years 5 months 8 days
Weighted average exercise price (in dollars per share)	$ 56.65
Exercisable number of shares (in shares)	9,538
Exercisable weighted average exercise price (in dollars per share)	$ 56.35

Stock-based compensation, Fair Value Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands						12 Months Ended
	Dec. 01, 2017	May 10, 2017	Dec. 06, 2016	Oct. 31, 2016	Jun. 07, 2016	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate - Minimum						1.98%	1.51%
Risk-free interest rate - Maximum						2.17%	2.18%
Volatility - Minimum						46.00%
Volatility - Maximum						48.00%
Volatility							50.00%
Expected dividend yield						0.00%	0.00%
Expected life						5 years 6 months	6 years 6 months
Estimated forfeiture rate						0.00%	0.00%
Stock-based compensation expense						$ 186	$ 113
Unrecognized compensation expense						$ 190
Weighted average period of recognition						1 year
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)						$ 1.23
Aggregate intrinsic value of options outstanding						$ 0
Aggregate intrinsic value of options exercisable						0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Aggregate fair value of shares issued						$ 279
Shares forfeited (in shares)						67,167
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expiry period of option						10 years
Stock Options [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)						201,501
Purchase price (in dollars per share)						$ 2.75
Stock Options [Member] \| December 6, 2016 [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)			90,000
Purchase price (in dollars per share)			$ 2.75
Term of vesting			1 year
Expiry period of option			10 years
Aggregate fair value of shares issued			$ 127
Stock Options [Member] \| October 31, 2016 [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)				108,501
Purchase price (in dollars per share)				$ 2.75
Term of vesting				3 years
Expiry period of option				10 years
Aggregate fair value of shares issued				$ 150
Stock Options [Member] \| June 7, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)					68,000
Purchase price (in dollars per share)					$ 3.75
Term of vesting					4 years
Expiry period of option					10 years
Aggregate fair value of shares issued					$ 128
Stock Options [Member] \| May 10, 2017 [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)		11,250
Purchase price (in dollars per share)		$ 2.78
Expiry period of option		10 years
Aggregate fair value of shares issued		$ 14
Stock Options [Member] \| December 1, 2017 [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)	90,000
Purchase price (in dollars per share)	$ 1.29
Term of vesting	1 year
Expiry period of option	10 years
Aggregate fair value of shares issued	$ 54

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current [Abstract]
Federal		$ 64	$ 0
State		11	15
Current income taxes		75	15
Deferred [Abstract]
Federal		(24)	178
State		78	62
Deferred income tax		54	240
Income tax expense		$ 129	255
Income Tax Disclosure [Line Items]
Federal corporate tax rate		34.00%
Difference between income tax benefit and U.S. federal income tax rate to pretax loss from continuing operations [Abstract]
Computed expected tax benefit		$ (6,359)	(1,047)
State tax benefit, net of federal effect		(1,113)	(499)
Warrant value fluctuation		(34)	(1,835)
Tax Cuts and Jobs Act impact		23,834	0
Net (decrease) increase in valuation allowance		(16,199)	3,636
Income tax expense		129	255
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforward		50,472	72,870
Intangible assets		4,595	8,711
Inventory		66	149
Reserves & accrued expenses		228	291
Convertible debt discount		0	(11,097)
Property & equipment		130	432
Non-cash compensation		793	1,127
Goodwill		(414)	(359)
Total deferred tax assets		55,870	72,124
Less: valuation allowance		(56,284)	(72,483)
Net deferred tax assets/(liabilities)		(414)	(359)
Valuation allowance - Deferred tax asset change in amount		(16,199)
Federal operating loss carryforwards, net		$ 181,413	$ 183,658
Earliest open tax year subject to examination		2014
Maximum [Member]
Income Tax Disclosure [Line Items]
Federal corporate tax rate		35.00%
Plan [Member]
Income Tax Disclosure [Line Items]
Federal corporate tax rate	21.00%

Business Segments and Geographic Data (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	3
Results of Operations from Business Segments [Abstract]
Revenues	$ 31,449	$ 30,707
Cost of revenues	13,498	12,636
Gross profit	$ 17,951	$ 18,071
Gross profit %	57.10%	58.80%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,711	$ 1,929
Selling and marketing expenses	11,249	12,102
Unallocated operating expenses	7,401	7,637
Total operating expenses	20,361	21,668
Income (loss) from operations	(2,410)	(3,597)
Interest expense, net	(4,612)	(4,900)
Change in fair value of warrant liability	102	5,396
Other income (expense), net	17	21
Loss on extinguishment of debentures	(11,799)	0
Loss before income taxes	(18,702)	(3,080)
Assets	38,631	43,193
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	22,640	23,508
Cost of revenues	8,744	8,763
Gross profit	$ 13,896	$ 14,745
Gross profit %	61.40%	62.70%
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,431	$ 1,288
Selling and marketing expenses	9,454	11,541
Unallocated operating expenses	0	0
Total operating expenses	10,885	12,829
Income (loss) from operations	3,011	1,916
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Loss on extinguishment of debentures	0
Loss before income taxes	3,011	1,916
Assets	29,722	34,612
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	8,792	7,065
Cost of revenues	4,529	3,506
Gross profit	$ 4,263	$ 3,559
Gross profit %	48.50%	50.40%
Allocated operating expenses [Abstract]
Engineering and product development	$ 279	$ 210
Selling and marketing expenses	1,795	375
Unallocated operating expenses	0	0
Total operating expenses	2,074	585
Income (loss) from operations	2,189	2,974
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Loss on extinguishment of debentures	0
Loss before income taxes	2,189	2,974
Assets	4,403	3,980
Operating Segments [Member] \| Dermatology Imaging [Member]
Results of Operations from Business Segments [Abstract]
Revenues	17	134
Cost of revenues	225	367
Gross profit	$ (208)	$ (233)
Gross profit %	(1223.50%)	(173.90%)
Allocated operating expenses [Abstract]
Engineering and product development	$ 1	$ 431
Selling and marketing expenses	0	186
Unallocated operating expenses	0	0
Total operating expenses	1	617
Income (loss) from operations	(209)	(850)
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Other income (expense), net	0	0
Loss on extinguishment of debentures	0
Loss before income taxes	(209)	(850)
Assets	0	265
Reportable Geographical Components [Member] \| Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues	26,178	24,486
Reportable Geographical Components [Member] \| Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,271	6,221
Other Unallocated Assets [Member]
Allocated operating expenses [Abstract]
Assets	$ 4,506	$ 4,336

Related Parties (Details) $ / shares in Units, $ in Thousands						12 Months Ended
	Sep. 14, 2017 shares	Jun. 06, 2017 shares $ / shares	Nov. 04, 2015 USD ($)	Jun. 22, 2015 USD ($) shares $ / shares	Jul. 21, 2014 USD ($) shares $ / shares	Dec. 31, 2017 USD ($) shares Director $ / shares	Dec. 31, 2016 USD ($)	Sep. 13, 2017 USD ($)
Related Party Transaction [Line Items]
Loss on extinguishment of debentures						$ (11,799)	$ 0
Number of directors \| Director						2
Related parties general and administrative expenses						$ 180	240
Series C Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt								$ 40,465
Number of shares debt convertible (in shares) \| shares						15,049,000
Initial conversion price (in dollars per share) \| $ / shares						$ 2.69
Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt						$ 32,500
Number of shares debt convertible (in shares) \| shares						8,666,668
Interest rate						2.25%
Initial conversion price (in dollars per share) \| $ / shares						$ 3.75
Maturity period						5 years
Maturity date						Jun. 30, 2021
Senior Secured 4% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt					$ 15,000	$ 15,000
Number of shares debt convertible (in shares) \| shares					1,169,595
Interest rate		4.00%				4.00%
Initial conversion price (in dollars per share) \| $ / shares					$ 12.825
Maturity period						5 years
Maturity date						Jun. 30, 2021
Debt conversion, converted instrument, issued (in shares) \| shares						70,000
Senior Secured 2.25% Convertible Debentures and Senior Secured 4% Convertible Debentures [Member] \| Series C Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Number of shares debt convertible (in shares) \| shares		15,049,000
Initial conversion price (in dollars per share) \| $ / shares		$ 2.69
Debt conversion, converted instrument, issued (in shares) \| shares	40,482
Sabby Management LLC and Broadfin LLC [Member]
Related Party Transaction [Line Items]
Number of shares underlying warrants (in shares) \| shares				600,000
Exercise price of warrants (in dollars per share) \| $ / shares				$ 3.75
Sabby Management LLC and Broadfin LLC [Member] \| Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Exercise price of warrants (in dollars per share) \| $ / shares				$ 3.75
Aggregate principal amount of debt				$ 32,500
Number of shares debt convertible (in shares) \| shares				8,666,668
Interest rate				2.25%
Initial conversion price (in dollars per share) \| $ / shares				$ 3.75
Maturity period						5 years
Maturity date						Jun. 30, 2021
Two Board Directors [Member]
Related Party Transaction [Line Items]
Up-front fee paid			$ 40
Monthly retainer fee						$ 10	$ 10
Olympic Media [Member]
Related Party Transaction [Line Items]
Up-front fee paid						$ 30
Period of written notice without penalty						10 days

Significant Customer Concentration (Details) - Customer Concentration Risk [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue [Member]
Product Information [Line Items]
Revenues	$ 5,264	$ 6,093
Concentration risk percentage	16.70%	19.80%
Accounts Receivable [Member]
Product Information [Line Items]
Accounts receivable	$ 475
Concentration risk percentage	15.10%

Subsequent Events (Details) $ / shares in Units, $ in Thousands			1 Months Ended
	Apr. 10, 2018 BoardMember	Mar. 30, 2018 USD ($) $ / shares shares	Jan. 31, 2018 shares	Oct. 31, 2017 shares
Series C Convertible Preferred Stock [Member]
Subsequent Events [Line Items]
Preferred stock converted in shares of common stock (in shares) \| shares				1,598,346
Subsequent Event [Member] \| Broadfin Capital [Member]
Subsequent Events [Line Items]
Percentage of blocker prior to record date for meeting of shareholders	9.99%	9.99%
Subsequent Event [Member] \| Sabby Management [Member]
Subsequent Events [Line Items]
Percentage of blocker prior to record date for meeting of shareholders	9.99%	9.99%
Subsequent Event [Member] \| Midcap Non-binding Letter of Intent [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 14,000
Repayment on current facility		3,000
Expected base amount of loan		$ 7,571
Term of loan		48 months
Term for payment of interest		18 months
Term for payment of principal amount		30 months
Percentage of blocker prior to record date for meeting of shareholders		19.99%
Subsequent Event [Member] \| Accelmed Stock Purchase Agreement [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 13,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		12,037,037
Professional fees		$ 400
Breakup fee		$ 600
Closing fee percentage		4.00%
Expected investment advisory fees		$ 680
Expected investment advisory retainer fees		100
Remaining balance of expected investment advisory fees		580
Subsequent Event [Member] \| Accelmed Stock Purchase Agreement [Member] \| Maximum [Member]
Subsequent Events [Line Items]
Professional fees		$ 500
Subsequent Event [Member] \| Accelmed Stock Purchase Agreement [Member] \| Minimum [Member]
Subsequent Events [Line Items]
Number of current board members they will resign \| BoardMember	5
Subsequent Event [Member] \| Broadfin Capital and Sabby Management Stock Purchase Agreements [Member]
Subsequent Events [Line Items]
Preferred stock, conversion price (in dollars per share) \| $ / shares		$ 1.296
Subsequent Event [Member] \| Broadfin Capital and Sabby Management Stock Purchase Agreements [Member] \| Broadfin Capital [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Broadfin Capital and Sabby Management Stock Purchase Agreements [Member] \| Sabby Management [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Subscription Agreement [Member] \| Broadfin Capital [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Subscription Agreement [Member] \| Sabby Management [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Subscription Agreement [Member] \| Gohan Investments, Ltd [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Subscription Agreement [Member] \| Dr. Dolev Rafaeli [Member]
Subsequent Events [Line Items]
Expected equity financing investment		$ 1,000
Share price (in dollars per share) \| $ / shares		$ 1.08
Expected equity financing investment (in shares) \| shares		925,926
Subsequent Event [Member] \| Series C Convertible Preferred Stock [Member]
Subsequent Events [Line Items]
Preferred stock converted in shares of common stock (in shares) \| shares			75,000